ASP Isotopes Q3 2026 shareholder loss widens to $30.4M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
ASP Isotopes Inc. (ASPI) reported third-quarter 2026 revenue of $5.124 million, versus $1.271 million a year earlier, while net loss attributable to shareholders widened to $30.371 million from $12.617 million. For the first nine months, revenue was $14.427 million versus $3.571 million; net loss from continuing operations was $91.567 million versus $96.802 million.
Net cash used in operating activities for the nine months was $66.449 million, compared with $19.935 million a year earlier. Cash and cash equivalents were $201.663 million at September 30, 2026; the company expects this cash to fund operating expenses and capital requirements for more than 12 months from issuance of the financial statements. Convertible notes payable at fair value were $85.860 million, compared with $199.323 million at December 31, 2025.
ASP Isotopes acquired Renergen in January 2026 and issued 14,270,000 shares in the acquisition. It deconsolidated Skyline on March 29, 2026, retaining approximately 8.6% of its outstanding Class A ordinary and preferred shares. Continuing operations include nuclear fuels, specialist isotopes and related services, and helium and LNG.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter revenue rose to $5.124 million from $1.271 million.
- Moderate pointNine-month continuing-operations loss narrowed to $91.567 million from $96.802 million.
Negative
- Moderate pointQuarterly shareholder-attributable loss widened to $30.371 million from $12.617 million.
- Moderate pointNine-month operating cash used rose to $66.449 million from $19.935 million.
Filing Explained
In the quarter, ASP Isotopes issued 23,160,682 common shares for convertible notes; the new shares increase the share count and reduce existing holders’ percentage ownership, absent offsetting changes.
Key Figures
Key Terms
HALEU technical
deconsolidation financial
Level 3 fair value financial
units-of-production method financial
asset retirement obligation financial
measurement alternative financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did ASPI report in Q3 2026?
How much did ASPI lose in Q3 2026?
How much operating cash did ASPI use in the first nine months of 2026?
How long does ASPI expect its cash to last?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from __________________ to __________________
Commission File Number:
(Exact Name of Registrant as Specified in its Charter) |
|
||
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
|
||
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
☒ |
Smaller reporting company |
||
|
|
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of November 16, 2026, the registrant had
Table of Contents
|
|
|
Page |
PART I. |
FINANCIAL INFORMATION |
|
5 |
Item 1. |
Financial Statements (Unaudited) |
|
5 |
|
Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 |
|
5 |
|
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Month Periods ended September 30, 2026 and 2025 |
|
6 |
|
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Month Periods ended September 30, 2026 and 2025 |
|
7 |
|
Condensed Consolidated Statements of Cash Flows for the Nine Month Periods ended September 30, 2026 and 2025 |
|
9 |
|
Notes to Unaudited Condensed Consolidated Financial Statements |
|
11 |
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|
39 |
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
|
53 |
Item 4. |
Controls and Procedures |
|
53 |
|
|
|
|
PART II. |
OTHER INFORMATION |
|
54 |
Item 1. |
Legal Proceedings |
|
54 |
Item 1A. |
Risk Factors |
|
54 |
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
|
54 |
Item 3. |
Defaults Upon Senior Securities |
|
54 |
Item 4. |
Mine Safety Disclosures |
|
54 |
Item 5. |
Other Information |
|
54 |
Item 6. |
Exhibits |
|
56 |
Signatures |
|
57 |
|
2
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “would,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Some of the key factors that could cause actual results to differ from our expectations include:
3
These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in Part I, Item 1A - “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 (as amended), and other reports that we file with the SEC, including this Quarterly Report on Form 10-Q. Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
This Quarterly Report on Form 10-Q also contains estimates, projections, and other information concerning our industry, our business, and the potential markets for certain isotopes and for helium and LNG, including data regarding the estimated size of those respective markets, their respective projected growth rates, and, in the case of our isotope enrichment platform, the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections, or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by third parties, industry, medical and general publications, government data, and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.
Note Regarding Company References
Unless the context otherwise requires, references to the “Company,” “our Company,” “ASPI,” “we,” “us” and “our” refer to ASP Isotopes Inc. and its direct and indirect subsidiaries; references to “ASP Isotopes” refer to ASP Isotopes Inc. and not to any of its subsidiaries; references to “QLE” refer to Quantum Leap Energy, LLC; references to “Renergen” refer to Renergen Limited, a public corporation incorporated in 2014 and existing under the South African Companies Act 71 of 2008, as amended, together with its subsidiaries unless the context dictates otherwise; references to “Tetra4” refer to Tetra4 Proprietary Limited; references to “Skyline” refer to Skyline Builders Group Holding Limited, together with its subsidiaries. The terms “dollar,” “USD” or “$” refer to U.S. dollars, and the terms “R,” “ZAR” or “rand” refer to the South African rand.
Trademarks
All trademarks, service marks, and trade names included in this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this report may be referred to without the ® and symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.
4
PART I-FINANCIAL INFORMATION
Item 1. Financial Statements.
ASP Isotopes Inc.
Condensed Consolidated Balance Sheets (unaudited)
(in thousands, except share and per share amounts)
|
|
September 30, 2026 |
|
|
December 31, 2025 * |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
|
$ |
|
||
Short-term investments |
|
|
|
|
|
|
||
Restricted cash |
|
|
|
|
|
|
||
Accounts receivable |
|
|
|
|
|
|
||
Inventories |
|
|
|
|
|
|
||
Note receivable |
|
|
|
|
|
|
||
Deferred offering costs |
|
|
|
|
|
|
||
Prepaid expenses and other current assets |
|
|
|
|
|
|
||
Current assets of discontinued operations |
|
|
|
|
|
|
||
Total current assets |
|
|
|
|
|
|
||
Property and equipment, net |
|
|
|
|
|
|
||
Natural gas properties, net |
|
|
|
|
|
|
||
Operating lease right-of-use assets, net |
|
|
|
|
|
|
||
Intangible assets |
|
|
|
|
|
|
||
Goodwill |
|
|
|
|
|
|
||
Lease receivable - noncurrent |
|
|
|
|
|
|
||
Restricted cash - noncurrent |
|
|
|
|
|
|
||
Equity method investments |
|
|
|
|
|
|
||
Other investments |
|
|
|
|
|
|
||
Other noncurrent assets |
|
|
|
|
|
|
||
Noncurrent assets of discontinued operations |
|
|
|
|
|
|
||
Total assets |
|
$ |
|
|
$ |
|
||
|
|
|
|
|
|
|
||
Liabilities and stockholders’ equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
|
|
$ |
|
||
Accrued expenses |
|
|
|
|
|
|
||
Debt - current |
|
|
|
|
|
|
||
Finance lease liabilities – current |
|
|
|
|
|
|
||
Operating lease liabilities – current |
|
|
|
|
|
|
||
Deferred revenue |
|
|
|
|
|
|
||
Other current liabilities |
|
|
|
|
|
|
||
Current liabilities of discontinued operations |
|
|
|
|
|
|
||
Total current liabilities |
|
|
|
|
|
|
||
Deferred tax liabilities |
|
|
|
|
|
|
||
Convertible notes payable, at fair value |
|
|
|
|
|
|
||
Debt - noncurrent |
|
|
|
|
|
|
||
Finance lease liabilities – noncurrent |
|
|
|
|
|
|
||
Operating lease liabilities – noncurrent |
|
|
|
|
|
|
||
Deferred revenue - noncurrent |
|
|
|
|
|
|
||
Other noncurrent liabilities |
|
|
|
|
|
|
||
Noncurrent liabilities of discontinued operations |
|
|
|
|
|
|
||
Total liabilities |
|
|
|
|
|
|
||
Commitments and contingencies (Note 11) |
|
|
|
|
|
|
||
Stockholders’ equity |
|
|
|
|
|
|
||
Preferred stock, $ |
|
|
|
|
|
|
||
Common stock, $ |
|
|
|
|
|
|
||
Treasury stock at cost |
|
|
|
|
|
|
||
Additional paid-in capital |
|
|
|
|
|
|
||
Accumulated deficit |
|
|
( |
) |
|
|
( |
) |
Accumulated other comprehensive income |
|
|
|
|
|
|
||
Total stockholders’ equity attributed to ASP Isotopes Inc. stockholders |
|
|
|
|
|
|
||
Noncontrolling interests in consolidated subsidiaries |
|
|
|
|
|
|
||
Total stockholders’ equity |
|
|
|
|
|
|
||
Total liabilities and stockholders’ equity |
|
$ |
|
|
$ |
|
||
* Reclassified to reflect discontinued operations presentation.
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
ASP Isotopes Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
(in thousands, except share and per share amounts)
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025* |
|
|
2026 |
|
|
2025* |
|
||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Collaboration revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Gross profit |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Loss from operations |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Other (expense) income: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Foreign exchange transaction loss |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Change in fair value of share liability |
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
||
Change in fair value of convertible notes payable |
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
||
Change in fair value of equity investments |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|||
Gain on extinguishment of convertible notes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Total other income (expense) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Loss before income tax expense |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Income tax expense |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Net loss from continuing operations |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Income from discontinued operations, net of taxes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Less: Net loss attributable to noncontrolling interests |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Net loss attributable to ASP Isotopes Inc. shareholders |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Net (loss) income per share, basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Continuing operations |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Discontinued operations |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Attributable to ASP Isotopes Inc. shareholders |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Weighted average shares of common stock outstanding, |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss before allocation to noncontrolling interests |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Foreign currency translation |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
|
|
||
Less: reclassification to earnings |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total comprehensive loss before allocation to noncontrolling interests |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Less: Comprehensive (loss) income attributable to noncontrolling interests |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
Total comprehensive loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
* Reclassified to reflect discontinued operations presentation.
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
ASP Isotopes Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited)
(in thousands, except share and per share amounts)
|
|
Common Stock |
|
|
Treasury |
|
|
Additional |
|
|
Accumulated |
|
|
Accumulated |
|
|
Noncontrolling |
|
|
Total Stockholders' |
|
|||||||||||||||
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Stock |
|
|
Capital |
|
|
(Loss) Income |
|
|
Deficit |
|
|
Interests |
|
|
Equity |
|
|||||||||
Balance as of December 31, 2025 |
|
|
|
|
$ |
|
|
|
— |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
$ |
|
|||||||
Issuance of common stock to acquire Renergen |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Forfeiture of restricted common stock |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Stock-based compensation expense |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Deconsolidation of subsidiary |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
|
|
( |
) |
||||
Fair value of noncontrolling interest at acquisition of Numed |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Fair value of noncontrolling interest at acquisition of Renergen |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Distribution to noncontrolling interest of Renergen |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
|||||
Contributions from noncontrolling interest |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Distribution to noncontrolling interest of VIE |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|||||
Foreign currency translation |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
( |
) |
|||||
Reclassification to earnings |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
||||||
Net loss - continuing operations |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
||||
Gain on deconsolidation |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Net income - discontinued operations |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Balance as of March 31, 2026 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
|
$ |
|
|||||||
Issuance of common stock from exercise of options |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Issuance of restricted common stock |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Forfeiture/cancellation of restricted common stock |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Distribution to noncontrolling interest of Renergen |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
|||||
Stock-based compensation expense |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Distribution to noncontrolling interest of VIE |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|||||
Foreign currency translation |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Net loss |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
||||
Balance as of June 30, 2026 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
$ |
|
||||||||
Issuance of restricted common stock |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Issuance of common stock for convertible notes |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Forfeiture/cancellation of restricted common stock |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Issuance of common stock from cashless exercise of options |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Stock-based compensation expense |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Distribution to noncontrolling interest of Renergen |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
|||||
Distribution to noncontrolling interest of VIE |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|||||
Foreign currency translation |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
||||||
Net loss |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
||||
Balance as of September 30, 2026 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
$ |
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
ASP Isotopes Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited)
(in thousands, except share and per share amounts)
|
|
Common Stock |
|
|
|
|
|
Treasury |
|
|
Additional |
|
|
Accumulated |
|
|
Accumulated |
|
|
Noncontrolling |
|
|
Total Stockholders' |
|
||||||||||||
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Stock |
|
|
Capital |
|
|
(Loss) Income |
|
|
Deficit |
|
|
Interests |
|
|
Equity |
|
|||||||||
Balance as of December 31, 2024 |
|
|
|
|
$ |
|
|
|
— |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
|
|
|
||||||
Stock-based compensation expense |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Distribution to noncontrolling interest of VIE |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|||||
Foreign currency translation |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Net loss |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
||||
Balance as of March 31, 2025 |
|
|
|
|
$ |
|
|
|
— |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
|
$ |
|
||||||
Issuance of common stock from public offering, net of issuance costs of $ |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Issuance of common stock from exercise of warrants |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Issuance of restricted common stock |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Settlement of liabilities with consultant |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Stock-based compensation expense |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Distribution to noncontrolling interest of VIE |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|||||
Foreign currency translation |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Net loss |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
||||
Balance as of June 30, 2025 |
|
|
|
|
$ |
|
|
|
— |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
$ |
|
|||||||
Issuance of common stock from public offering, net of issuance costs of $ |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Issuance of common stock from cashless exercise of warrants |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Issuance of common stock from cashless exercise of options |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Issuance of restricted common stock |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Stock-based compensation expense |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Fair value of noncontrolling interest at acquisition of Skyline |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Distribution to noncontrolling interest of VIE |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|||||
Foreign currency translation |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Net loss - continuing operations |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
||||
Net income - discontinued operations |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Balance as of September 30, 2025* |
|
|
|
|
$ |
|
|
|
— |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
$ |
|
|||||||
* Reclassified to reflect discontinued operations presentation.
The accompanying notes are an integral part of these condensed consolidated financial statements.
8
ASP Isotopes Inc.
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)
|
|
Nine Months Ended September 30, |
|
|||||
|
|
2026 |
|
|
2025* |
|
||
Cash flows from Operating activities |
|
|
|
|
|
|
||
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
Adjustments to reconcile net loss to cash used in operating activities: |
|
|
|
|
|
|
||
Income from discontinued operations |
|
|
( |
) |
|
|
( |
) |
Foreign exchange transaction loss from intercompany |
|
|
|
|
|
|
||
Depreciation, depletion and amortization |
|
|
|
|
|
|
||
Gain on deconsolidation |
|
|
( |
) |
|
|
|
|
Gain on sale of property and equipment |
|
|
( |
) |
|
|
|
|
Noncash write-off of capitalized costs |
|
|
|
|
|
|
||
Non cash interest income on note receivable |
|
|
|
|
|
( |
) |
|
Non cash interest expense on debt |
|
|
|
|
|
|
||
Stock-based compensation |
|
|
|
|
|
|
||
Shares issued for non-cash consultant expense |
|
|
|
|
|
|
||
Change in fair value of share liability |
|
|
|
|
|
|
||
Gain on extinguishment of convertible notes payable |
|
|
( |
) |
|
|
|
|
Change in fair value of convertible notes payable |
|
|
|
|
|
|
||
Change in fair value of equity investments |
|
|
( |
) |
|
|
|
|
Change in right-of-use lease asset |
|
|
|
|
|
|
||
Non-cash lease income |
|
|
( |
) |
|
|
( |
) |
Change in deferred taxes |
|
|
|
|
|
|
||
Changes in operating assets and liabilities, net of acquisition amounts: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
( |
) |
|
|
|
|
Receivable from noncontrolling interest |
|
|
|
|
|
|
||
Inventories |
|
|
( |
) |
|
|
( |
) |
Prepaid expenses and other current assets |
|
|
( |
) |
|
|
|
|
Other noncurrent assets |
|
|
( |
) |
|
|
|
|
Accounts payable |
|
|
|
|
|
( |
) |
|
Accrued expenses |
|
|
|
|
|
|
||
Operating lease liabilities |
|
|
( |
) |
|
|
( |
) |
Other current liabilities |
|
|
|
|
|
( |
) |
|
Other noncurrent liabilities |
|
|
|
|
|
|
||
Net cash used in operating activities – continuing operations |
|
|
( |
) |
|
|
( |
) |
Cash used in operating activities – discontinued operations |
|
|
( |
) |
|
|
( |
) |
Net cash used in operating activities |
|
|
( |
) |
|
|
( |
) |
Cash flows from investing activities |
|
|
|
|
|
|
||
Purchases of property and equipment |
|
|
( |
) |
|
|
( |
) |
Purchases of short-term investments |
|
|
( |
) |
|
|
|
|
Proceeds from maturity of short-term investments |
|
|
|
|
|
|
||
Principal collections from lease receivable |
|
|
|
|
|
|
||
Proceeds from sale of property and equipment |
|
|
|
|
|
|
||
Purchase of equity investments |
|
|
( |
) |
|
|
( |
) |
Cash received (paid) for acquisition of business, net of cash paid |
|
|
|
|
|
( |
) |
|
Cash disposed of upon deconsolidation of subsidiary |
|
|
( |
) |
|
|
( |
) |
Cash advance in exchanges for note receivable |
|
|
|
|
|
( |
) |
|
Net cash used in investing activities – continuing operations |
|
|
( |
) |
|
|
( |
) |
Net cash provided by investing activities – discontinued operations |
|
|
|
|
|
|
||
Net cash used in investing activities |
|
|
( |
) |
|
|
( |
) |
Cash flows from financing activities |
|
|
|
|
|
|
||
Proceeds from issuance of common stock |
|
|
|
|
|
|
||
Payment of common stock issuance costs |
|
|
( |
) |
|
|
( |
) |
Proceeds from exercise of warrants |
|
|
|
|
|
|
||
Proceeds from exercise of options |
|
|
|
|
|
|
||
Distribution to noncontrolling interest in VIE |
|
|
( |
) |
|
|
( |
) |
Distribution to noncontrolling interest of Renergen |
|
|
( |
) |
|
|
|
|
Proceeds from issuance of debt |
|
|
|
|
|
|
||
Payment of principal portion of debt |
|
|
( |
) |
|
|
( |
) |
Payment of principal portion of finance leases |
|
|
( |
) |
|
|
( |
) |
Net cash (used in) provided by financing activities – continuing operations |
|
|
( |
) |
|
|
|
|
Cash provided by financing activities – discontinued operations |
|
|
|
|
|
|
||
Net cash provided by financing activities |
|
|
|
|
|
|
||
Net change in cash, cash equivalents and restricted cash |
|
|
( |
) |
|
|
|
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
|
( |
) |
|
|
|
|
Cash, cash equivalents and restricted cash - beginning of period |
|
|
|
|
|
|
||
Cash, cash equivalents and restricted cash - end of period |
|
$ |
|
|
$ |
|
||
Components of cash, cash equivalents, and restricted cash |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
|
$ |
|
||
Restricted cash |
|
|
|
|
|
|
||
Total cash, cash equivalents, and restricted cash |
|
$ |
|
|
$ |
|
||
* Reclassified to reflect discontinued operations presentation.
The accompanying notes are an integral part of these condensed consolidated financial statements.
9
ASP Isotopes Inc.
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)
Supplemental cash flow information: |
|
|
|
|
|
|
||
Cash paid for Interest |
|
$ |
|
|
$ |
|
||
Supplemental disclosures of non-cash investing and financing activities: |
|
|
|
|
|
|
||
Derecognition of asset as a result of sales-type lease |
|
$ |
|
|
$ |
|
||
Lease receivable |
|
$ |
|
|
$ |
|
||
Purchase of property and equipment included in accounts payable |
|
$ |
|
|
$ |
|
||
Purchase of property and equipment with bank loans |
|
$ |
|
|
$ |
|
||
Right-of-use asset obtained in exchange for operating lease liability |
|
$ |
|
|
$ |
|
||
Right-of-use asset obtained in exchange for finance lease liability |
|
$ |
|
|
$ |
|
||
Common stock issued in acquisition of Renergen |
|
$ |
|
|
$ |
|
||
Consideration relating to obligated purchase for acquisition of Numed |
|
$ |
|
|
$ |
|
||
Issuance of common stock for the purchase of QLE convertible notes |
|
$ |
|
|
$ |
|
||
The accompanying notes are an integral part of these condensed consolidated financial statements.
10
ASP Isotopes Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
1. Organization
Description of Business
ASP Isotopes Inc. was incorporated in the state of Delaware on September 13, 2021 and has its headquarters in Dallas, Texas. ASP Isotopes Inc., its subsidiaries and ASP Rentals (Pty) Ltd ("ASP Rentals") are collectively referred to as “the Company” throughout these condensed consolidated financial statements.
The Company is an advanced materials company dedicated to the development of a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. Our proprietary enrichment technologies, the Aerodynamic Separation Process (“ASP technology”) and Quantum Enrichment technology (“QE technology”), are designed to enable the production of isotopes for a range of industrial and advanced technology applications. Our initial focus is on the production and commercialization of enriched Carbon-14 (“C-14”), Silicon-28 (“Si-28”) and Ytterbium-176 (“Yb-176”). The Company's commercial radiodiagnostic activities are currently focused on radiopharmaceutical products used in positron emission tomography ("PET") and single-photon emission computed tomography ("SPECT") imaging, as well as therapeutic radiopharmaceuticals used in the treatment of oncology indications.
Quantum Leap Energy LLC (“QLE”), the Company's subsidiary, is currently pursuing an initiative to apply its enrichment technologies to the enrichment of Uranium-235 (“U-235”) in South Africa. The Company believes that the U-235 QLE may produce has the potential to be commercialized as a nuclear fuel component for use in the new generation of high-assay low-enriched uranium (“HALEU”)-fueled small modular reactors that are now under development for commercial and government uses. In furtherance of the Company's uranium enrichment initiative, in October 2024, the Company entered into a term sheet with TerraPower, LLC (“TerraPower”) which contemplates the parties entering into definitive agreements pursuant to which TerraPower would provide funding for the construction of a HALEU production facility and agree to purchase all HALEU produced at the facility over a 10-year period after the planned completion of the facility. In addition, in November 2024, the Company entered into a memorandum of understanding with The South African Nuclear Energy Corporation (“Necsa”), a South African state-owned company responsible for undertaking and promoting research and development in the field of nuclear energy and radiation sciences, to collaborate on the research, development and ultimately the commercial production of advanced nuclear fuels. As part of the collaboration contemplated by the MOU with Necsa, QLE’s South African subsidiary has entered into a Pre-Implementation Services Contract Agreement (“Services Contract”) with Necsa, pursuant to which Necsa has agreed to provide to QLE’s South African subsidiary certain facilities, infrastructure, utilities and services related to the siting, design, construction, commission and operation of an enrichment facility on the Necsa site in Pelindaba. See the section captioned “TerraPower” below (Note 13) for disclosures regarding certain definitive agreements entered into between TerraPower and us and/or the Company's subsidiaries, including a term loan subject to conditions to support construction of a new uranium enrichment facility at Pelindaba, South Africa and supply agreements for the future supply of HALEU to TerraPower, as a customer.
QLE acquired a controlling interest in Skyline in August 2025. Skyline is a holding company, and its operations are conducted through its wholly owned operating subsidiaries, Kin Chiu Engineering Limited and Kin Chiu Development Company Limited. Operations primarily consist of construction activities which include public civil engineering works, such as road and drainage works, in Hong Kong. Skyline mostly undertakes civil engineering works in the role as a subcontractor but is fully qualified to undertake such works in the capacity of a main contractor. QLE intends to pursue opportunities to acquire assets in the critical materials supply chain.
QLE entered into the Securities Exchange Agreement (the "Exchange Agreement") with a third party, effective as of March 29, 2026, which resulted in the deconsolidation of Skyline (Note 21). QLE retained approximately
The Company acquired Renergen in January 2026. Renergen is South Africa’s leading onshore natural gas explorer and the first integrated producer of both liquid helium and LNG, both of which are produced from the natural gas reserve base that underpins Renergen’s natural gas development project (the “Virginia Gas Project”). The Virginia Gas Project includes (i) the liquefaction of natural gas into LNG, (ii) the separation of helium from natural gas, and (iii) the further liquefaction of helium into 99.999% pure liquid helium. This liquefaction and separation takes place at Renergen’s natural gas processing plant in the Free State Province of South Africa. Renergen’s principal asset is its
Liquidity
The Company has incurred net losses and negative cash flows from operating activities since its inception. The Company incurred net losses from continuing operations of $
There can be no assurance that the Company will achieve or sustain positive cash flows from operations or profitability. The Company anticipates it will need to continue to raise capital through additional equity and/or debt financings and/or collaborative development agreements to fund its operations. However, such funding may not be available on a timely basis on terms acceptable to the Company, or at all. If the Company is unable to raise additional capital when required or on acceptable terms, the Company may be required to scale back or discontinue the advancement of product candidates, reduce headcount, reorganize, merge with another entity, or cease operations.
2. Basis of Presentation and Summary of Significant Accounting Policies
Unaudited Financial Information
The Company’s unaudited condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"), and pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the Company’s opinion, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.
11
The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes for the year ended December 31, 2025.
Basis of Presentation and Use of Estimates
The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and disclosure in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s condensed consolidated financial statements relate to stock-based compensation, fair value of convertible notes, equity and other investments, gas reserves, provisions for environmental rehabilitation, loss contingencies and the accounting for acquisitions, including goodwill. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.
The Company has reclassified certain prior-year amounts to conform to the current-year’s presentation. The accounting requirements for reporting the separation of Skyline as a discontinued operation were met when the deconsolidation was completed on March 29, 2026. Accordingly, the historical results of Skyline are presented as discontinued operations and, as such, have been excluded from continuing operations and segment results for all periods presented. Refer to Note 21, “Discontinued Operations,” for additional information.
Principles of consolidation
Currency and currency translation
Concentration of Credit Risk and other Risks
Cash balances are maintained at U.S. financial institutions and may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit of $
The Company's foreign subsidiaries held cash of approximately $
The Company is potentially subject to concentrations of credit risk in accounts receivable. There was
Although the Company is directly affected by the financial condition of its customers, management does not believe significant credit risks existed as of September 30, 2026. Generally, the Company does not require customers to post collateral or other securities to support our associated accounts receivable.
There was
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents are stated at fair value and may include money market funds, U.S. Treasury and U.S. government-sponsored agency securities, corporate debt, commercial paper and certificates of deposit. The Company had cash equivalents totaling $
12
Restricted Cash
Restricted cash represents cash balances that are legally or contractually restricted as to withdrawal or use. Restricted cash is classified as current or noncurrent on the condensed consolidated balance sheet based on the nature and expected timing of the underlying restriction. Amounts classified as restricted cash are excluded from cash and cash equivalents and are disclosed separately on the balance sheet. As of September 30, 2026, the Company had current restricted cash of $
Fair Value of Financial Instruments
Accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1: Observable inputs such as quoted prices in active markets;
Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
The Company’s convertible notes payable (Note 9) is measured as a Level 3 fair value on a recurring basis.
Equity Method and Other Investments
The Company accounts for investments in entities over which it has significant influence, but not control, using the equity method of accounting in accordance with ASC Topic 323, Investments - Equity Method and Joint Ventures ("ASC 323"). Significant influence is generally presumed when the Company owns
Under the equity method, the Company has elected the fair value option, under which it initially recorded the investment at fair value and subsequently adjusts the carrying amount to reflect its share of the investee’s earnings or losses, which are recognized in the condensed consolidated statements of operations and comprehensive loss. Dividends received from equity method investees reduce the carrying amount of the investment. The Company evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Alternatively, the Company may elect to utilize the fair value option. The Company's equity method investments include the Company's investment in Skyline utilizing the fair value option.
The Company also holds investments in equity securities without readily determinable fair values. These investments are accounted for under the measurement alternative in accordance with ASC Topic 321, Investments - Equity Securities ("ASC 321"), which allows the Company to record the investments at cost, less impairments, plus or minus observable price changes in orderly transactions for the identical or similar investment. The Company's investments recorded at cost include IsoBio, Inc. ("IsoBio") and Opeongo, Inc. ("Opeongo").
If the Company determines that an impairment is other-than-temporary, it recognizes a loss equal to the difference between the investment’s carrying amount and its fair value. Equity method investments and investments at cost are included in “Equity method investments” and "Other investments", respectively, on the condensed consolidated balance sheet.
Accounts Receivable
Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for expected credit losses is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management's evaluation of outstanding accounts receivable. The Company maintains an allowance for expected credit losses for accounts receivable, which is recorded as an offset to accounts receivable, and changes in such are classified as selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. The Company assesses collectability by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when the Company identifies specific customers with known disputes or collectability issues. In determining the amount of the allowance for expected credit losses, the Company considers historical collectability based on past due status and make judgments about the creditworthiness of customers based on ongoing credit evaluations. The Company also considers customer-specific information and current market conditions. Bad debts are written off against the allowance when identified. As of September 30, 2026 and December 31, 2025 there was
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first in, first out inventory method. Inventory cost includes materials, labor, and applicable overhead incurred in bringing the inventories to their present location and condition. Net realizable value represents the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are primarily located in facilities in South Africa and are not pledged as collateral for any debt arrangements
13
The components of inventories as of September 30, 2026 and December 31, 2025 were as follows (in thousands):
|
|
September 30, |
|
|
December 31, |
|
||
Raw material |
|
$ |
|
|
$ |
|
||
Work in process |
|
|
|
|
|
|
||
Finished goods |
|
|
|
|
|
|
||
Total inventories |
|
$ |
|
|
$ |
|
||
No significant write-downs to net realizable value or reversals of write-downs occurred in the three and nine months ended September 30, 2026 and 2025.
Property and Equipment
Property and equipment include costs of assets constructed, purchased or leased under a finance lease, related delivery and installation costs and interest incurred on significant capital projects during their construction periods. Expenditures for renewals and betterments also are capitalized, but expenditures for normal repairs and maintenance are expensed as incurred. Costs associated with yearly planned major maintenance are generally deferred and amortized over 12 months or until the same major maintenance activities must be repeated, whichever is shorter. The cost and accumulated depreciation applicable to assets retired or sold are removed from the respective accounts, and gains or losses thereon are included in the statement of operations and comprehensive loss.
The Company assigns the useful lives of its property and equipment based upon its internal engineering estimates, which are reviewed periodically. The estimated useful lives of the Company's property and equipment range from
Construction in progress (Note 6) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account, including, but not limited to, leasehold improvements or other such accounts.
Business Combination and Asset Acquisitions
The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations ("ASC 805"), which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.
The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the condensed consolidated statements of operations and comprehensive loss.
If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given.
Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.
Goodwill and Identifiable Intangible Assets
Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Identifiable intangible assets recognized in conjunction with acquisitions are recorded at fair value. Significant unobservable inputs are used to determine the fair value of the identifiable intangible assets based on the income approach valuation model, whereby the present worth and anticipated future benefits of the identifiable intangible assets are discounted back to their net present value.
Goodwill and identifiable intangible assets with indefinite lives are not amortized and are subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill or identifiable intangible assets are impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company performs its annual test for goodwill or identifiable intangible assets as of October 31.
14
Identifiable intangible assets with definite lives are amortized over their estimated useful lives, ranging from
Natural Gas Producing Activities
Effective January 6, 2026, the Company consolidates Renergen Limited and its subsidiaries, including Tetra4 Proprietary Limited, which holds South Africa’s first onshore petroleum production right. The Company’s natural gas producing activities are located entirely in South Africa (Free State Province). The Company follows the successful efforts method of accounting for its natural gas producing activities. Under this method, property acquisition costs and development costs are capitalized when incurred and depleted on a units-of-production basis over the remaining life of proved reserves and proved developed reserves, respectively. Unproved reserve assets and the related costs are transferred to proved reserve assets when proved reserves are found, or otherwise attributed to, the property.
The Company initially capitalizes exploratory well costs pending a determination whether proved reserves have been found. If proved reserves are found, costs remain capitalized; if no proved reserves are found or a well is uneconomic, costs are charged to expense. Other exploration costs, including geological and geophysical costs, are expensed as incurred. Costs to operate and maintain wells and field equipment are expensed as incurred.
Proved reserve assets and proved developed assets are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in accordance with ASC 360, Property, Plant and Equipment. As of September 30, 2026, no impairment indicators were identified with respect to Renergen’s proved properties.
The Company performs periodic assessments of unproved properties for impairment and recognizes a loss at the time of impairment. In determining whether an unproved property is impaired, the Company considers numerous factors including, but not limited to, current development and exploration drilling plans, favorable or unfavorable exploration activity on adjacent lands, and in-house geologists’ evaluation of the reservoir. As of September 30, 2026,
Impairment of Long-lived Assets
Long-lived assets consist primarily of property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset is not recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets. The Company did
Asset Retirement Obligations
The Company accounts for legal obligations associated with the retirement of its natural gas properties in accordance with ASC 410-20, Asset Retirement and Environmental Obligations. An asset retirement obligation ("ARO") is recognized at fair value in the period in which it is incurred and when a reasonable estimate of fair value can be made. Upon initial recognition, the fair value of the ARO is capitalized as part of the carrying amount of the related long-lived asset (the "rehabilitation asset") and included in property and equipment, net, in the condensed consolidated balance sheets.
The ARO is measured at the present value of estimated future cash flows required to satisfy the retirement obligation, discounted at a credit-adjusted risk-free rate that reflects current market assessments of the time value of money and the risks specific to the liability. In subsequent periods, the liability is increased for the passage of time through accretion expense, which is recognized within cost of revenue. Revisions to the timing or amount of estimated future cash flows result in an adjustment to both the carrying amount of the ARO liability and the related rehabilitation asset.
The Company has production and exploration rights on land in South Africa. A rehabilitation obligation of $
The ARO was recognized at fair value on the acquisition date discounted at a pre-tax rate of
Revenue Recognition
The Company recognizes revenue in accordance with Accounting Standard Codification ("ASC") Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.
The Company evaluates a transaction’s performance obligations to determine if promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers whether the goods or services are integral or dependent to other goods or services in the contract. The Company determines the transaction price based on the agreed government rates for the promised goods in the contract. The consideration is recognized as revenue when control is transferred for the related goods.
15
The Company enters into revenue generating transactions with certain customers that include payment for delivery of nuclear medical doses from its radiopharmacies in South Africa and the U.S. for PET and SPECT scanning. Revenue from its radiopharmacies is recognized upon delivery.
The Company’s collaboration revenue relates to TerraPower LLC ("TerraPower") (Note 13). At contract execution, the Company analyzes its collaborative arrangements and license agreements to assess whether both parties are active participants in the activities and are exposed to significant risks and rewards and therefore are within the scope of ASC 808, Collaborative arrangements (“ASC 808”). ASC 808 does not address the recognition and measurement of payments from collaborative arrangements and instead refers companies to use other authoritative accounting literature. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and therefore are within the scope of ASC 606, Revenue from Contracts with Customers. When the Company determines elements of a collaboration agreement do not reflect a vendor-customer relationship, the Company consistently applies a reasonable and rational policy election made by analogizing to authoritative accounting literature. The Company evaluates the income statement classification for presentation of amounts due from or owed to other participants in a collaboration arrangement based on the nature of each separate activity. The Company recognizes collaboration revenue from TerraPower as contractual deliverables are provided and the related performance obligations are satisfied. Amounts received in advance of performance are recorded as deferred revenue and recognized as revenue when the associated services or deliverables are transferred to the collaborator.
In January 2026, the Company acquired Renergen (Note 14). Renergen explores, produces and sells LNG in South Africa. Revenue from the sale of LNG is recognized upon delivery to the specified destination agreed to in the contract.
When consideration is received from a customer prior to transferring goods or services to the customer under the terms of long-term contracts, a token liability is recorded. The Company classifies these token liabilities within “Deferred revenue - noncurrent” on the Company’s condensed consolidated balance sheets since they have no expiration date. Token contract liabilities are recognized as revenue after control of the goods and services is transferred to the customer and all revenue recognition criteria have been met. The token liability was $
Recently Issued Accounting Pronouncements
The Company has reviewed recently issued accounting pronouncements and plans to adopt those that are applicable to it. The Company does not expect the adoption of any recently issued pronouncements to have a material impact on its results of operations or financial position.
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”) and is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. ASU 2024-03 requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The Company is still assessing the impact of adopting this standard.
In August 2025, the FASB issued ASU 2025-08, Financial Instruments—Credit Losses (Topic 326): Purchased Loans (“ASU 2024-08”) and is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years with early adoption permitted. ASU 2025-08 clarifies the accounting for purchased loans under the current expected credit loss (CECL) model, including guidance on recognizing and measuring expected credit losses and presentation of related amounts. The Company is still assessing the impact of adopting this standard.
In September 2025, the FASB issued ASU 2025-06, Targeted Improvements to the Accounting for Internal-Use Software ("ASU 2025-06") and is effective January 1, 2028 with early adoption permitted. ASU 2025-06 modernizes the accounting for internal use software costs and requires entities to start capitalizing eligible costs when (1) management has authorized and committed to funding the software project, and (2) it is probable that the project will be completed and the software will be used to perform the function intended. The guidance can be applied on a prospective basis, a modified basis for in-process projects, or a retrospective basis. The Company is still assessing the impact of adopting this standard.
3. Short-term Investments
The Company had no held-to-maturity investments as of September 30, 2026.
|
|
Year Ended December 31, 2025 |
|
|||||||||||||
|
|
Amortized Cost |
|
|
Unrealized Gains |
|
|
Unrealized Losses |
|
|
Fair Value |
|
||||
U.S. Treasury securities - mature April 2026 |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Total |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
There is
4. Fair Value Measurements
The Company classified its U.S. Treasury securities (Note 3) within Level 2 because their fair values are determined using alternative pricing sources or models that utilized market observable inputs. The Company’s convertible notes payable (Note 9) is measured as a Level 3 fair value on a recurring basis and was $
The Company holds an equity investment in IsoBio. The Company originally measured the investment at cost. In October 2025, IsoBio completed a preferred stock financing with unrelated third‑party investors. The transaction represented an observable price change for an identical or other similar equity security held by the Company. Accordingly, the Company remeasured the investment to fair value and recorded an unrealized gain of $
The Company holds an equity investment in Opeongo. The Company measured the investment at cost and no observable price changes were identified. The carrying value of the Opeongo investment is $
16
The Company holds an equity investment in ENDRA Life Sciences, Inc. ("ENDRA"), consisting of common stock, pre-funded common stock warrants and common stock warrants. The Company measured the investment at fair value. The original carrying amount recorded in May 2026 was $
The Company holds an equity investment in Skyline. The Company measured the investment under the equity method and recorded the investment at $
There were
A summary of the assets and liabilities that are measured at fair value as of September 30, 2026 and December 31, 2025 is as follows (in thousands):
|
|
September 30, 2026 |
|
|||||||||||||
|
|
Carrying Value |
|
|
Quoted Price in Active Markets for Identical Assets (Level 1) |
|
|
Significant Other Observable Inputs (Level 2) |
|
|
Significant Unobservable Inputs (Level 3) |
|
||||
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
U.S. Treasury securities |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Equity method investments |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other investments (ASC 321) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Convertible notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
December 31, |
|
|||||||||||||
|
|
Carrying Value |
|
|
Quoted Price in Active Markets for Identical Assets (Level 1) |
|
|
Significant Other Observable Inputs (Level 2) |
|
|
Significant Unobservable Inputs (Level 3) |
|
||||
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
U.S. Treasury securities |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Other investments (ASC 321) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Convertible notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
The following table provides a reconciliation of the Company’s liabilities measured as a Level 3 at fair value on a recurring basis using significant unobservable inputs (in thousands):
|
|
Convertible |
|
|
Balance as of December 31, 2024 |
|
$ |
|
|
Fair value at issuance |
|
|
|
|
Fair value adjustment |
|
|
|
|
Balance as of December 31, 2025 |
|
|
|
|
Issuance of common stock for convertible notes |
|
|
( |
) |
Fair value adjustment |
|
|
|
|
Balance as of September 30, 2026 |
|
$ |
|
|
5. Revenue and Segment Information
In connection with the Company's acquisitions of
17
The following table presents revenue from continuing operations disaggregated by geography based on the Company’s locations (in thousands):
|
|
Revenues |
|
|||||||||||||
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
Segment |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
South Africa |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
United States |
|
|
|
|
|
|
|
|
|
|
||||||
Total Revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
The following table presents changes in the Company’s accounts receivable for the nine months ended September 30, 2026 (in thousands):
|
|
Balance as of |
|
|
Additions (a) |
|
|
Deductions |
|
|
Balance as of |
|
||||
Accounts receivable |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||
Segment Information
Beginning in 2024, primarily as a result of increased business activities of its subsidiary, Quantum Leap Energy LLC, the Company had
The specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Molybdenum-100 (“Mo-100"), Si-28 and Yb-176) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging and semiconductors, as well as services related to these isotopes, and this segment includes operations of PET Labs, Numed and ECNP.
The nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market, and this segment includes operations of QLE.
The Helium and LNG segment is currently focused on the exploration, production and sale of helium and LNG in South Africa, and this segment includes operations of Renergen.
The Company’s chief operating decision maker (“CODM”) is its chief executive officer.
In addition, the CODM reviews segment revenue and segment gross profit (loss) to evaluate pricing, customer mix, and direct cost performance within each segment. The CODM also reviews net income (loss) before income taxes to assess the overall financial performance of each segment and to facilitate comparisons among segments. The CODM regularly reviews any asset information by operating segment as well and, accordingly, asset information is reported on a segment basis.
The following table shows total assets by segment and a reconciliation to the condensed consolidated financial statements as of September 30, 2026 and December 31, 2025 (in thousands):
|
|
September 30, |
|
|
December 31, |
|
||
Segment assets: |
|
|
|
|
|
|
||
Specialist isotopes and related services |
|
$ |
|
|
$ |
|
||
Nuclear fuels |
|
|
|
|
|
|
||
Helium and LNG |
|
|
|
|
|
|
||
Discontinued operations |
|
|
|
|
|
|
||
Total assets |
|
$ |
|
|
$ |
|
||
Select information from the condensed consolidated statements of operations and comprehensive loss as of the three months ended September 30, 2026 and 2025 is as follows (in thousands):
|
|
Revenues |
|
|
Segment Operating Loss |
|
||||||||||
|
|
Three Months Ended September 30, |
|
|
Three Months Ended September 30, |
|
||||||||||
Segment |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Specialist isotopes and related services |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
||
Nuclear fuels |
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
||
Helium and LNG |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|||
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
||
18
Select information from the condensed consolidated statements of operations and comprehensive loss as of the nine months ended September 30, 2026 and 2025 is as follows (in thousands):
|
|
Revenues |
|
|
Segment Operating Loss |
|
||||||||||
|
|
Nine Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
Segment |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Specialist isotopes and related services |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
||
Nuclear fuels |
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
||
Helium and LNG |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|||
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
||
A reconciliation of total segment revenue to total consolidated revenue and of total segment gross profit and segment operating income to total consolidated income before income taxes, for the three months ended September 30, 2026 and 2025, is as follows (in thousands):
|
|
Three Months Ended September 30, 2026 |
|
|||||||||||||
|
|
Specialist isotopes and related services |
|
|
Nuclear fuels |
|
|
Helium and LNG |
|
|
Total |
|
||||
Product revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Less: cost of sales |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
|
( |
) |
|
Segment gross profit (loss) |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|||
Personnel expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Professional fees |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other segment expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Segment operating loss |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Foreign exchange transaction loss |
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
Change in fair value of investments |
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
||
Change in fair value of convertible notes payable |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|||
Gain on extinguishment of convertible notes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income (expense), net |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|||
Loss before income tax expense |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
|
Three Months Ended September 30, 2025 |
|
|||||||||
|
|
Specialist isotopes and related services |
|
|
Nuclear fuels |
|
|
Total |
|
|||
Product revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|||
Less: cost of sales |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
Segment gross profit |
|
|
|
|
|
|
|
|
|
|||
Personnel expenses |
|
|
|
|
|
|
|
|
|
|||
Professional fees |
|
|
|
|
|
|
|
|
|
|||
Other segment expenses |
|
|
|
|
|
|
|
|
|
|||
Segment operating loss |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Foreign exchange transaction loss |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
Change in fair value of share liability |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
Change in fair value of convertible notes payable |
|
|
|
|
|
|
|
|
|
|||
Interest income, net |
|
|
|
|
|
|
|
|
|
|||
Loss before income tax expense |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
A reconciliation of total segment revenue to total consolidated revenue and of total segment gross profit and segment operating income to total consolidated income before income taxes, for the nine months ended September 30, 2026 and 2025, is as follows (in thousands):
|
|
Nine Months Ended September 30, 2026 |
|
|||||||||||||
|
|
Specialist isotopes and related services |
|
|
Nuclear fuels |
|
|
Helium and LNG |
|
|
Total |
|
||||
Product revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Collaboration revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Less: cost of sales |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
|
( |
) |
|
Segment gross profit (loss) |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|||
Personnel expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Professional fees |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other segment expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Segment operating loss |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Foreign exchange transaction loss |
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
Change in fair value of investments |
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|||
Change in fair value of convertible notes payable |
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
||
Gain on extinguishment of convertible notes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income (expense), net |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|||
Loss before income tax expense |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
19
|
|
Nine Months Ended September 30, 2025 |
|
|||||||||
|
|
Specialist isotopes and related services |
|
|
Nuclear fuels |
|
|
Total |
|
|||
Product revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|||
Less: cost of sales |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
Segment gross profit |
|
|
|
|
|
|
|
|
|
|||
Personnel expenses |
|
|
|
|
|
|
|
|
|
|||
Professional fees |
|
|
|
|
|
|
|
|
|
|||
Other segment expenses |
|
|
|
|
|
|
|
|
|
|||
Segment operating loss |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Foreign exchange transaction loss |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
Change in fair value of share liability |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
Change in fair value of convertible notes payable |
|
|
|
|
|
( |
) |
|
|
( |
) |
|
Interest income, net |
|
|
|
|
|
|
|
|
|
|||
Loss before income tax expense |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Other segment expenses primarily consist of selling and marketing expenses, professional fees, occupancy costs, information technology expenses, insurance, depreciation and amortization, and other general and administrative expenses that are regularly provided to the CODM and included in the measure used to determine segment operating loss.
6. Property and Equipment
Property and equipment as of September 30, 2026 and December 31, 2025 consisted of the following (in thousands):
|
|
Useful Lives |
|
September 30, |
|
|
December 31, |
|
||
Construction in progress |
|
— |
|
$ |
|
|
$ |
|
||
Plant and office buildings |
|
|
|
|
|
|
|
|||
Land |
|
— |
|
|
|
|
|
|
||
Tools, machinery and equipment |
|
|
|
|
|
|
|
|||
Computer equipment |
|
|
|
|
|
|
|
|||
Vehicles |
|
|
|
|
|
|
|
|||
Software |
|
|
|
|
|
|
|
|||
Office furniture |
|
|
|
|
|
|
|
|||
Leasehold improvements |
|
Lesser of estimated useful life or the remaining lease term |
|
|
|
|
|
|
||
Property and equipment, at cost |
|
|
|
|
|
|
|
|
||
Less accumulated depreciation |
|
|
|
|
( |
) |
|
|
( |
) |
Property and equipment, net |
|
|
|
$ |
|
|
$ |
|
||
The Company has three isotope enrichment plants in Pretoria, South Africa: a C-14 plant, a multi-isotope plant and a laser isotope separation plant using QE technology. As of September 30, 2026 costs incurred for the expansion of PET Labs South Africa were considered construction in progress because the work was not complete. As of December 31, 2025, costs incurred for the expansion of PET Labs South Africa and the improvements to the laser isotope separation plant were considered construction in progress because the work was not complete.
Depreciation expense was $
Natural gas properties at cost as of September 30, 2026 and December 31, 2025 consisted of the following (in thousands):
|
|
September 30, |
|
|
December 31, |
|
||
Proved reserves |
|
$ |
|
|
$ |
|
||
Unproved reserves |
|
|
|
|
|
|
||
Wells in process |
|
|
|
|
|
|
||
Developed Assets |
|
|
|
|
|
|
||
Gas processing and liquefaction equipment (Virginia Gas Project) |
|
|
|
|
|
|
||
Construction in progress |
|
|
|
|
|
|
||
Rehabilitation Asset |
|
|
|
|
|
|
||
Natural gas properties, at cost |
|
|
|
|
|
|
||
Less accumulated depreciation, depletion and amortization |
|
|
( |
) |
|
|
|
|
Net capitalized costs |
|
$ |
|
|
$ |
|
||
Natural gas properties are depleted using the unit-of-production method. Acquisition costs (proved reserves) are depleted over total proved reserves; development costs (developed assets) are depleted over proved developed reserves. Gas processing and liquefaction equipment, including the plant, is depreciated using the straight-line method based on a useful life of
20
7. Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets as of September 30, 2026 and December 31, 2025 consisted of the following (in thousands):
|
|
September 30, |
|
|
December 31, |
|
||
Value-added tax refund receivable |
|
$ |
|
|
$ |
|
||
Insurance |
|
|
|
|
|
|
||
Vendor advances and deposits |
|
|
|
|
|
|
||
Lease receivable |
|
|
|
|
|
|
||
Other |
|
|
|
|
|
|
||
Total prepaid expenses and other current assets |
|
$ |
|
|
$ |
|
||
8. Accrued Expenses
Accrued expenses as of September 30, 2026 and December 31, 2025 consisted of the following (in thousands):
|
|
September 30, |
|
|
December 31, |
|
||
Salaries and other employee costs |
|
$ |
|
|
$ |
|
||
Professional |
|
|
|
|
|
|
||
Other |
|
|
|
|
|
|
||
Total accrued expenses |
|
$ |
|
|
$ |
|
||
9. Debt
Debt consisted of the following as of September 30, 2026 and December 31, 2025 (in thousands):
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
Promissory notes |
|
$ |
|
|
$ |
|
||
Motor vehicle and equipment loans |
|
|
|
|
|
|
||
Credit facility |
|
|
|
|
|
|
||
Secured term loans |
|
|
|
|
|
|
||
Unsecured term loans |
|
|
|
|
|
|
||
Total debt |
|
|
|
|
|
|
||
less current portion of debt |
|
|
( |
) |
|
|
( |
) |
Long term portion of debt |
|
$ |
|
|
$ |
|
||
Credit facility and term loans contain a repayment on demand clause. Management believes the carrying values of debt outstanding approximates fair value based on the interest rates and scheduled maturities applicable to the outstanding borrowings.
Promissory Note Payable
In August 2025, the Company executed a promissory note payable with a finance company to fund a general liability insurance policy for $
In August 2026, the Company executed a promissory note payable with a finance company to fund a general liability insurance policy for $
The Company assumed a promissory note in connection with the acquisition of Renergen in January 2026 to fund a general liability insurance policy for approximately $
Motor Vehicle and Equipment Loans
Periodically, the Company enters into loans to purchase motor vehicles and certain equipment. For the nine months ended September 30, 2026, the Company entered into new loans totaling $
Credit Facilities
Renergen's subsidiary Tetra4 entered into a $
21
Office in the Project Country; (b) its failure to timely deliver its audited annual financial statements, the related auditor reports and the Sponsor’s audited annual financial statements to DFC following Tetra4’s transition from IFRS to US GAAP and the extended PCAOB‑compliant audit procedures required to align with ASPI’s SEC periodic reporting obligations; and (c) cross-default provision of the DFC Credit Facility, which was triggered by Tetra4’s breaches of the IDC Loan Agreement. Tetra4 is actively engaged in discussions with DFC regarding the aforementioned defaults, and, while there can be no assurance that DFC will agree to an amendment or waiver on acceptable terms (or at all), DFC has informally indicated its willingness (i) to extend the deadline for the registration of the Servitude Security to a date falling six months after the anticipated completion date for Phase 1 of the Virginia Gas Project and (ii) to consider extending such audited annual financial statements delivery deadline to no later than the fourth quarter 2026. Failure to obtain such amendments or waivers from DFC could result in DFC exercising remedies available to it under the DFC Credit Facility, including declaring any portion or all of the outstanding principal amount and accrued interest thereon immediately due and payable. As a result of these defaults, DFC may be entitled to accelerate the DFC Credit Facility, which in turn give rise to an event of default under the cross-default provisions of the SBSA Loan. For the period January 6, 2026 through September 30, 2026, interest expense under the DFC Credit Facility was $
Secured Term Loans
Renergen's subsidiary Tetra4 entered into a ZAR
Pursuant to a Secured Term Loan Facility Agreement, Renergen obtained a ZAR
22
financial statements for the fiscal year ended February 28, 2026 within the required periods, and the breaches by Tetra4 under the IDC Loan Agreement and the DFC facility, which entitle those lenders to accelerate the relevant loans, constituted an event of default under the cross-default provisions of the SBSA Loan. As at the date of this report, SBSA has not exercised any remedies in respect of these events of default; however, there can be no assurance that it will not do so. The SBSA Loan outstanding on September 30, 2026 amounted to ZAR
Unsecured Term Loans
Renergen entered into a $
Renergen's subsidiary Tetra4 entered into a ZAR
As the loan was not repaid on August 31, 2024 it now accrues interest at the prime lending rate plus
In November 2024, Molopo initiated legal proceedings against Tetra4 in the High Court of South Africa, Gauteng Local Division, Johannesburg, by issuing a summons alleging a breach of contract when Renergen sold the
Scheduled maturities of the Company’s debt as of September 30, 2026 are as follows (in thousands):
2026 (remaining three months) |
|
$ |
|
|
2027 |
|
|
|
|
2028 |
|
|
|
|
2029 |
|
|
|
|
2030 |
|
|
|
|
Thereafter |
|
|
|
|
Total notes payable |
|
$ |
|
|
Less debt - current |
|
|
( |
) |
Debt -noncurrent |
|
$ |
|
Convertible Notes Payable
In March 2024, QLE issued convertible notes payable (“March 2024 Convertible Notes”) totaling $
In June 2024, QLE issued additional convertible notes payable (“June 2024 Convertible Notes”) totaling $
The 2024 Convertible Notes were recorded on the condensed consolidated balance sheet at their fair values. The fair value of the March 2024 Convertible Notes on the date of issuance was $
In November 2025, QLE issued convertible notes payable (“2025 Convertible Notes”) totaling $
23
of an IPO or other qualifying public transaction at
On July 15, 2026, QLE and ASP entered into separate, individually negotiated private securities exchange agreements with certain holders of the 2025 Convertible Notes, pursuant to which such noteholders exchanged approximately $
The 2025 Convertible Notes are recorded on the condensed consolidated balance sheet at their fair values. The fair value of the 2025 Convertible Notes as of September 30, 2026 and December 31, 2025 has been determined to be $
TerraPower Loan Agreement
The Company announced QLE and certain of its subsidiaries have entered into a loan agreement with TerraPower (the “TerraPower Loan Agreement”), a US nuclear innovation company, for a multiple advance term loan of up to $
10. Deferred Revenues
In June 2023, the Company entered into a Supply Agreement with a customer for the delivery of Mo-100 and molybdenum-98 beginning in 2024. In conjunction with the Supply Agreement, the Company received $
The Company assumed a token liability in connection with the acquisition of Renergen in January 2026. Tokens to acquire helium at a fixed price with a value of $
11. Commitments and Contingencies
Commitments
Share Purchase Agreement relating to PET Labs
On October 31, 2023, the Company entered into a Share Purchase Agreement with Nucleonics Imaging Proprietary Limited, a company incorporated in the Republic of South Africa (the “Seller”), relating to the purchase and sale of ordinary shares in the issued share capital of PET Labs. PET Labs is a South African radiopharmaceutical operations company, dedicated to nuclear medicine and the science of radiopharmaceutical production.
Under the Purchase Agreement, the Company agreed to purchase from the Seller
PET Labs Global
In August 2024, PET Labs Global entered into a three-year service agreement with Cayman Enterprise City and is licensed to operate from within the Cayman Islands’ Special Economic Zone (“SEZ”). The service fee includes among other things the right to use certain office space and associated facilities within the SEZ. The Company has applied the guidance in ASC 842 and determined that this agreement is not a leasing arrangement. Management has determined that based on the nature of the combined services the expense should be recognized as incurred.
Renergen Firm Intention Letter and Loan Agreement
On March 31, 2025, the Company entered into an Exclusivity Agreement with Renergen, an entity in South Africa listed on the Johannesburg Stock Exchange (“JSE”), the Australian Stock Exchange and the A2X. On May 18, 2025, the Exclusivity Agreement was amended. Per the terms of the amended Exclusivity Agreement, the Company received the rights to negotiate the terms of the acquisition of Renergen during an exclusive negotiation period that ended on May 31, 2025. In April 2025, the Company paid an exclusivity fee of $
As contemplated in the Exclusivity Agreement signed on March 31, 2025 and amended on May 18, 2025, the Company entered into a Firm Intention Letter with Renergen on May 19, 2025. The Firm Intention Letter sets the acquisition terms for the Company to purchase
24
was consummated on January 6, 2026, and as a result, Renergen became a direct, wholly owned subsidiary of the Company, and the Renergen Ordinary Shares were delisted from the JSE, the Australian Securities Exchange and the A2X (Note 14).
In addition, the Company entered into a loan agreement with Renergen ("Renergen Loan") in which a total of $
Certain Commitments to the South Africa Competition Commission
In connection with the Company's acquisition of Renergen, the Company made certain commitments to the South Africa Competition Commission designed to address public interest concerns and promote historically disadvantaged persons (“HDP”) and worker ownership. These commitments to the South Africa Competition Commission include: (1) a moratorium on retrenchments of workers at Renergen’s operations for a period of two years from the merger closing date; and (2) a commitment to implement, within 12 months of the merger closing date, a trust for the benefit of qualifying workers employed by Renergen and certain HDP communities and people located within the production rights area of the Virginia Gas Project (the “HDP and Worker Trust”). Upon the effective implementation date of the HDP and Worker Trust, the HDP and Worker Trust are expected to hold an aggregate
Contingencies
From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues liabilities for such matters when future expenditures are probable and such expenditures can be reasonably estimated.
On December 4, 2024, a purported stockholder of the Company filed a putative securities class action on behalf of purchasers of the Company’s securities between October 30, 2024 through November 26, 2024 against ASP Isotopes Inc. and certain of its executive officers in the United States District Court for the Southern District of New York (Corredor v. ASP Isotopes Inc., et al., Case No. 1:24-cv-09253 (S.D.N.Y.)) (the “Securities Class Action”). The Securities Class Action alleges that the Company, its chief executive officer and chief financial officer (“Defendants”) made materially misleading or false statements or omissions regarding the Company’s business and asserts purported claims under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and SEC Rule 10b-5 promulgated thereunder. The complaint seeks unspecified compensatory damages, attorney’s fees and costs. On May 2, 2025, the Court appointed Mark Leone (“Leone”) as lead plaintiff and directed the Clerk of court to amend the caption to substitute Leone for Alexander Corredor as plaintiff. On May 2, 2025, the Court also appointed lead counsel and set deadlines for filing an amended consolidated class action complaint and briefing schedules for a motion to dismiss, if any, and class certification. On May 27, 2025, Leone and two additional named plaintiffs (“Plaintiffs”) filed the amended class action complaint (“Amended Complaint”), that asserts the same causes of action and seeks the same relief as the initial complaint and is based upon substantially similar factual allegations as the initial complaint. On June 27, 2025, Defendants filed a motion to dismiss the Amended Complaint. Also on June 27, 2025, Plaintiffs filed a motion for class certification. On December 4, 2025, the Court denied in part Defendants’ motion to dismiss and granted Plaintiffs’ motion for class certification. On April 3, 2026, following a mediation in which the parties reached an agreement-in-principle to resolve all claims in the Securities Class Action, subject to the Court’s approval, the parties filed a Joint Stipulation agreeing to stay the Securities Class Action (the “Stipulation”). On April 6, 2026, the Court approved the Stipulation. On July 7, 2026, Plaintiffs filed a motion for preliminary approval of the settlement. The motion for preliminary approval of the settlement also requested that the Court certify the settlement class and approve the proposed notice to stockholders. On July 9, 2026, the Court granted such motion, issued an order preliminarily approving the settlement, and scheduled a settlement hearing for December 15, 2026. Under the proposed settlement, the Plaintiffs are expected to receive $
On January 30, 2026, a purported stockholder of the Company filed a derivative action against certain members of the Company’s board of directors in the United States District Court for the Northern District of Texas asserting claims for, among others, breach of fiduciary duty, violation of § 14(a) of the Exchange Act and a claim for contribution pursuant to § 21D thereof (Jenis v. Mann, et al., Case No. 3:26-cv-251 (N.D. Tex.)) (the “Jenis Action”). The Company is named as a Nominal Defendant. On March 2, 2026, a different purported stockholder of the Company filed a derivative action against certain members of the Company’s board of directors in the United States District Court for the Southern District of New York asserting claims for, among others, breach of fiduciary duty, violations of §§ 14(a) and 20(a) of the Exchange Act, and a claim for contribution pursuant to § 21D thereof (Stewart v. Mann, et al., Case No. 1:26-cv-1712 (S.D.N.Y.)) (the “Stewart Action”)). The Company is named as a Nominal Defendant. On June 10, 2026, a different purported stockholder of the Company filed a derivative action against certain members of the Company’s board of directors in the United States District Court for the Northern District of Texas asserting claims for, among others, breach of fiduciary duty, violations of §§ 10(b) and 14(a) of the Exchange Act, and a claim for contribution pursuant to § 21D thereof (Albers v. Mann, et al., Case No. 3:26-cv-1923 (N.D. Tex.)) (the “Albers Action”). The Company is named as a Nominal Defendant. On July 1, 2026, a different purported stockholder of the Company filed a derivative action against certain members of the Company’s board of directors in the United States District Court for the Southern District of New York asserting claims for, among others, breach of fiduciary duty and violation of § 14(a) of the Exchange Act (Manrique v. Mann, et al., Case No. 1:26-cv-5580 (S.D.N.Y.)) (the “Manrique Action”) (together with the Jenis Action, the Stewart Action, and the Albers Action, the “Derivative Actions”). The Company is named as a Nominal Defendant. The Derivative Actions arise out of similar allegations as those made in the Securities Class Action. The plaintiffs in the Derivative Actions seek unspecified damages, disgorgement of compensation, corporate governance reforms, fees, interests, and costs. On July 2, 2026 and July 7, 2026, the Courts in the Stewart Action and Jenis Action, respectively, upon joint motions by the parties, issued orders staying the action in light of the parties’ settlement discussions. The Company cannot be certain of the outcome of the Derivative Actions and, if decided adversely to us, our business and financial condition may be adversely affected.
25
In November 2024, Molopo Energy Limited ("Molopo") initiated legal proceedings against Tetra4 in the High Court of South Africa, Gauteng Local Division, Johannesburg, by issuing a summons alleging breach of a written loan agreement concluded between Molopo, as lender, and Tetra4, as borrower, in April 2014 (the "Molopo Loan Action"). The Molopo Loan Action alleges that Renergen, Tetra4's parent company, breached a condition of the loan agreement when it sold a
In addition to the matters described above, from time to time, the Company may become subject to arbitration, litigation or claims arising in the ordinary course of business. The results of any current or future claims or proceedings cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and litigation costs, diversion of management resources, reputational harm and other factors.
12. Leases
Operating leases
The Company is party to several facility leases in South Africa and the U.S. for office, manufacturing and laboratory space. Dr. Gerdus Kemp, an officer of PET Labs and an employee of ASP UK, is the sole owner of a leased office and production facility in Pretoria, South Africa. During 2026, the Company has expanded its facility leases in South Africa and entered into a lease for office space in Dallas, Texas, which serves as its corporate headquarters, and Austin, Texas, which serves as QLE's corporate headquarters. In conjunction with the acquisition of Renergen in January 2026, the Company recognized additional operating leases for its office space in South Africa. The Company also leases office and production space in Pretoria, South Africa and Cayman Islands that are accounted for as short-term leases.
Quantitative information regarding the Company’s operating lease liabilities is as follows (in thousands):
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Operating Lease Cost |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating lease cost |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Other Information |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating cash flows paid for amounts included in the |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Operating lease liabilities arising from obtaining right-of- |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Weighted average remaining lease term (years) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted average discount rate |
|
|
% |
|
|
% |
|
|
% |
|
|
% |
||||
Future lease payments under noncancelable operating lease liabilities as of September 30, 2026 are as follows (in thousands):
|
|
Operating |
|
|
Future Lease Payments |
|
|
|
|
2026 (remaining three months) |
|
$ |
|
|
2027 |
|
|
|
|
2028 |
|
|
|
|
2029 |
|
|
|
|
2030 |
|
|
|
|
Thereafter |
|
|
|
|
Total lease payments |
|
$ |
|
|
Less: imputed interest |
|
|
( |
) |
Total operating lease liabilities |
|
$ |
|
|
Less current portion |
|
$ |
( |
) |
Operating lease liability - noncurrent |
|
$ |
|
|
The Company records the expense from short-term leases as incurred. Lease expense from short-term leases was $
Financing leases
The Company is party to several ongoing finance leases in South Africa for vehicles and equipment. Some of these finance leases include arrangements with variable interest rates indexed to the prime interest rate in South Africa. There was
26
Quantitative information regarding the Company’s finance lease liabilities is as follows (in thousands):
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Finance Lease Cost |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest on lease liabilities |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Other Information |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating cash flows paid for amounts included in the |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Amortization of right-of-use assets |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Weighted average remaining lease term (years) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted average discount rate |
|
|
% |
|
|
% |
|
|
% |
|
|
% |
||||
Future lease payments under noncancelable finance lease liabilities are as follows as of September 30, 2026 (in thousands):
|
|
Finance |
|
|
Future Lease Payments |
|
|
|
|
2026 (remaining three months) |
|
$ |
|
|
2027 |
|
|
|
|
2028 |
|
|
|
|
2029 |
|
|
|
|
2030 |
|
|
|
|
Thereafter |
|
|
|
|
Total lease payments |
|
$ |
|
|
Less: imputed interest |
|
|
( |
) |
Total lease liabilities |
|
$ |
|
|
Less current portion |
|
$ |
( |
) |
Finance lease liability - noncurrent |
|
$ |
|
|
Lease receivable
The Company leases certain equipment to customers under sales-type leases and records the leases within lease receivables on the Company’s condensed consolidated balance sheets and records interest income in the Company’s condensed consolidated statements of operations and comprehensive loss. The Company does not have significant variable lease payments or residual value guarantees associated with these leases. Credit risk is monitored regularly, and no allowance for credit losses was recorded as of the reporting date.
The Company’s net investment in sales-type leases were comprised of the following (in thousands):
|
|
September 30, 2026 |
|
|
Total undiscounted cash flows |
|
$ |
|
|
Present value discount |
|
|
( |
) |
Net investment in sales-type leases |
|
$ |
|
|
Less current portion |
|
$ |
( |
) |
Net investment in sales-type leases - noncurrent |
|
$ |
|
|
The current portion of sales-type leases is included in prepaid and other current assets on the balance sheet.
Future minimum lease payments to be collected under sales-type leases, excluding lease payments that are not fixed and determinable, as of September 30, 2026 are as follows (in thousands):
|
|
Sales-type |
|
|
Future Lease Payments To Be Collected |
|
|
|
|
2026 (remaining three months) |
|
$ |
|
|
2027 |
|
|
|
|
2028 |
|
|
|
|
2029 |
|
|
|
|
2030 |
|
|
|
|
Thereafter |
|
|
|
|
Total undiscounted cash flows |
|
$ |
|
|
Interest income recognized from sales-type leases during the three and nine months ended September 30, 2026 was $
13. License and Collaboration Agreements
TerraPower, LLC
TerraPower Agreement
On April 4, 2024, the Company entered into an agreement with TerraPower LLC (“TerraPower”) to develop a conceptual design, refined cost/schedule/financing, risk register, and term sheet for a HALEU facility (the “TerraPower R&D Agreement”). The TerraPower R&D Agreement may be terminated for (a) breach or default, (b) the Company’s convenience or (c) TerraPower’s convenience. TerraPower is obligated to make all payments for tasks completed by the Company per the statement of work in the TerraPower R&D Agreement totaling $
27
On October 18, 2024, the Company and TerraPower signed a term sheet (the “TerraPower Term Sheet”) that provides for the execution of two definitive agreements: (1) an agreement pursuant to which TerraPower will provide funding for the Company’s construction of a uranium enrichment facility capable of producing HALEU using the Company’s proprietary aerodynamic separation process technology to be located in the Republic of South Africa and (2) an agreement pursuant to which the Company will deliver to TerraPower the full capacity of the enrichment facility.
The Company accounts for the TerraPower R&D Agreement as a collaboration arrangement in accordance with ASC 808. The Company has concluded that other authoritative accounting literature does not apply directly to these payments from TerraPower, either directly or by analogy, including ASC 606 because TerraPower is not a customer. The Company has concluded that TerraPower is not a customer because TerraPower has not contracted with the Company to obtain goods or services that are an output of the Company’s ordinary activities in exchange for consideration. The Company also has concluded that there is no other authoritative accounting literature that is appropriate to apply by analogy, and, accordingly, its accounting policy is to evaluate the income statement classification for presentation of amounts associated with each separate activity. As a result, the Company concludes that all portions of the net receivable from TerraPower are directly related to the conceptual design of the HALEU facility. Furthermore, the Company and TerraPower will jointly develop criteria for optimization of the HALEU facility’s operations. TerraPower shares the risks and rewards of designing the HALEU facility since its successful completion will enable TerraPower to purchase output from the HALEU facility in the future.
For the nine months ended September 30, 2026, $
TerraPower Loan Agreement and HALEU Supply Agreements
In May 2025, the Company entered into the TerraPower Loan Agreement, which provides conditional commitments from TerraPower to the Company through one of its wholly-owned U.S.-based subsidiaries (“Borrower”) for a multiple advance term loan totaling $
In addition to the Terra Power Loan Agreement, the Company and TerraPower have entered into two supply agreements for the HALEU expected to be produced at the Company’s uranium enrichment facility. The initial core supply agreement is intended to support the supply of the required first fuel cores for the initial loading of TerraPower’s Natrium project in Wyoming. The long-term supply agreement is a 10-year supply agreement of up to a total of 150 metric tons of HALEU, commencing in 2028 through end of 2037.
American Ventures Advisory Agreement
On October 28, 2025, QLE entered into an Advisory Agreement (“Advisory Agreement”) with American Ventures LLC, a Delaware limited liability company (“American Ventures”). Under the Advisory Agreement, American Ventures will provide various services to the Company related to QLE and its present and future subsidiaries’ business and operations.
In October 2025, pursuant to the Advisory Agreement,
14. Acquisitions and Merger Agreement
The Company accounts for business combinations in accordance with Business Combinations (Topic 805), which requires an acquirer to retrospectively adjust provisional amounts recognized in a business combination during the measurement period (which represents a period not to exceed one year from the date of the acquisition), in the reporting period in which the adjustment is determined, as well as present separately on the face of the income statement or as a disclosure in the notes to the condensed consolidated financial statements, the portion of the amount recorded in current period earnings that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date.
PET Labs Acquisition
In October 2023, the Company completed the acquisition of PET Labs. The acquisition is intended to accelerate the distribution of the Company’s nuclear medicine pipeline.
Pursuant to the terms of the agreement, the Company acquired
In addition to the purchase consideration, the Company has an option to purchase the remaining
Dr. Gerdus Kemp is an officer of PET Labs and, effective November 1, 2023, an employee of ASP Guernsey. In addition, Dr. Kemp controls the remaining
28
East Coast Nuclear Pharmacy Acquisition
In October 2025, the Company completed the acquisition of ECNP. The acquisition is intended to supplement the distribution of the Company’s nuclear medicine pipeline. The acquisition of ECNP has been accounted for as a business combination in accordance with ASC 805.
Pursuant to the terms of the agreement, the Company acquired
The following table summarizes the allocation of the purchase consideration to the fair value of the assets acquired and liabilities assumed (in thousands):
Fair value of business combination |
|
|
|
|
Cash consideration |
|
$ |
|
|
Notes payable to Sellers |
|
|
|
|
Identifiable assets acquired and liabilities assumed |
|
|
|
|
Cash and cash equivalents |
|
|
|
|
Accounts receivable |
|
|
|
|
Inventory |
|
|
|
|
Prepaid expenses and other current assets |
|
|
|
|
Identifiable intangible assets |
|
|
|
|
Accounts payable |
|
|
( |
) |
Other current liabilities |
|
|
( |
) |
Total identifiable assets acquired and liabilities assumed |
|
|
|
|
Goodwill |
|
|
|
|
Total purchase consideration |
|
$ |
|
|
Goodwill arising from the acquisition as of October 1, 2025 of $
One 30 Seven Inc. ("One 30 Seven") Acquisition
In October 2025, QLE acquired substantially all of the assets, including an international patent application and its related rights, from One 30 Seven, a Canadian company engaged in the business of researching and developing decontamination solutions for nuclear waste, particularly radioactive waste from radioactive materials from nuclear power plants, radiopharmaceuticals, and military sources. QLE made an initial cash payment of $
In connection with the acquisition of assets from One 30 Seven, QLE entered into a consulting agreement with B-Con Engineering Inc., led by inventor Brian Creber, to develop and validate the functional operation of a Creber Mini Unit designed to accelerate the beta decay of high-level waste and rapidly convert these long half-life isotopes into stable isotopes at an estimated cost of $
The Company determined that the cost to acquire the One 30 Seven assets was $
Numed Diagnostics, LLC Acquisition
In January 2026, the Company completed the acquisition of Numed Diagnostics, LLC ("Numed"). The acquisition is intended to supplement the distribution of the Company’s pipeline. The acquisition of Numed has been accounted for as a business combination in accordance with ASC 805.
Pursuant to the terms of the agreement, the Company acquired
29
The following table summarizes the preliminary allocation of the purchase consideration to the fair value of the assets acquired and liabilities assumed (in thousands):
Fair value of business combination |
|
|
|
|
Cash consideration |
|
$ |
|
|
Obligated Consideration |
|
|
|
|
Identifiable assets acquired and liabilities assumed |
|
|
|
|
Cash and cash equivalents |
|
|
|
|
Accounts receivable |
|
|
|
|
Inventory |
|
|
|
|
Property and equipment, net |
|
|
|
|
Other noncurrent assets |
|
|
|
|
Identifiable intangible assets |
|
|
|
|
Accounts payable |
|
|
( |
) |
Deferred tax liabilities |
|
|
( |
) |
Other current liabilities |
|
|
( |
) |
Total identifiable assets acquired and liabilities assumed |
|
|
|
|
Goodwill |
|
|
|
|
Noncontrolling interest |
|
|
( |
) |
Total purchase consideration |
|
$ |
|
|
Goodwill arising from the acquisition as of January 22, 2026 of $
The initial allocation of the purchase price was based upon a preliminary valuation, and accordingly, our estimates and assumptions are subject to change as we obtain additional information during the measurement period.
Renergen Acquisition
On
The following table summarizes the preliminary allocation of the purchase consideration to the fair value of the assets acquired and liabilities assumed (in thousands):
Fair value of business combination |
|
|
|
|
Equity consideration |
|
$ |
|
|
Cash consideration |
|
|
|
|
Note receivable |
|
|
|
|
Identifiable assets acquired and liabilities assumed |
|
|
|
|
Cash and cash equivalents |
|
|
|
|
Restricted cash - short term |
|
|
|
|
Accounts receivable |
|
|
|
|
Lessor Receivable |
|
|
|
|
Restricted cash - long term |
|
|
|
|
Inventory |
|
|
|
|
Property and equipment, net |
|
|
|
|
Natural gas properties |
|
|
|
|
Operating lease right-of-use asset, net |
|
|
|
|
Accounts payable |
|
|
( |
) |
Finance lease liabilities – current |
|
|
( |
) |
Operating lease liabilities – current |
|
|
( |
) |
Borrowings |
|
|
( |
) |
Deferred revenue |
|
|
( |
) |
Finance lease liabilities – noncurrent |
|
|
( |
) |
Operating lease liabilities – noncurrent |
|
|
( |
) |
Other liabilities - long term |
|
|
( |
) |
Deferred tax liabilities |
|
|
( |
) |
Total identifiable assets acquired and liabilities assumed |
|
|
|
|
Noncontrolling interest |
|
|
( |
) |
Total purchase consideration |
|
$ |
|
|
Prior to closing the acquisition of Renergen, the Company advanced $
In accordance with ASC 805, the Company measured the consideration transferred at fair value as of the acquisition date. The fair value of the note receivable was determined to be approximately $
30
closing, the contractual terms were consistent with market participant assumptions, and there were no significant changes in credit risk or other factors that would have resulted in a material difference between carrying value and fair value.
Natural gas properties represent the estimated fair value assigned to Renergen’s interests associated with the Virginia Gas Project in South Africa. As of the Acquisition Date, natural gas properties consisted primarily of proved reserves, developed assets, wells in process, construction-in-progress related to natural gas properties and capitalized asset retirement costs.
Proved reserves represent acquisition-date amounts attributed to proved reserve interests and are depleted using the unit-of-production method based on estimated total proved reserves. Developed assets primarily represent developed production, gathering, processing and liquefaction infrastructure and are depleted using the unit-of-production method based on estimated proved developed reserves. Wells in process and construction-in-progress related to natural gas properties represent development projects that had not yet been placed into service as of the Acquisition Date and therefore were not subject to depletion. Capitalized asset retirement costs represent the asset retirement cost associated with environmental restoration and abandonment obligations and are depleted consistent with the related developed assets.
The Company engaged an independent third party valuation specialist to estimate the fair value of the acquired property and equipment. The valuation relied primarily on a third party petroleum engineer’s reserve report for reserve quantities and future production forecasts and associated cash flows.
The initial allocation of the purchase price was based upon a preliminary valuation, and accordingly, our estimates and assumptions are subject to change as we obtain additional information during the measurement period.
Renergen's principal asset is its 94.5% equity ownership in Tetra4, which owns an onshore petroleum production right and is engaged in the exploration and production of natural gas and the processing of natural gas into liquid natural gas and liquid helium in Free State Province, South Africa. Mahlako Gas Energy Limited (“MGE”) has a 5.5% equity ownership in Tetra4. MGE, Renergen and Tetra are parties to a Sale, Subscription and Shareholders’ Agreement, dated December 22, 2023 (the “SSSA”), pursuant to which MGE acquired its equity in Tetra4 for ZAR 550 million. Under the SSSA, Renergen granted to MGE a put option related to MGE's equity (the “Put Option”) exercisable upon the occurrence of a Put Option Event (as defined in the SSSA). The price payable for MGE’s equity under the Put Option is calculated pursuant to a formula set forth in the SSSA, but will be not less than the aggregate of (i) the purchase price of MGE's equity paid by MGE (ZAR 550 million) plus the face value of any claims, (ii) 3.5% of such purchase price, and (iii) MGE's documented due diligence costs.
ENDRA Merger Agreement
On June 25, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among ENDRA Life Sciences Inc., a Delaware corporation (“ENDRA”), Noble Africa LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of the Company (“Noble”), Renergen and Kruger Merger Sub LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of ENDRA (“Merger Sub”), pursuant to which Merger Sub will merge with and into Noble (the “Merger”), with Noble surviving the Merger as a direct wholly-owned subsidiary of ENDRA.
Concurrently with the entry into the Merger Agreement, Noble entered into subscription agreements (“Subscription Agreements”) with the Company and certain investors pursuant to which Noble agreed to sell approximately (i)
Additionally, prior to the effective time of the Merger (the “Effective Time”), the Company will contribute all of its equity interest in Renergen to Noble in exchange for
Consummation of the Merger is subject to certain closing conditions, including, the approval by the shareholders of ENDRA, the receipt by Noble of the proceeds of the Noble Investment, Noble’s receipt of a written consent of the U.S. Internal Development Finance Corporation (formerly known as the Overseas Private Investment Corporation) (“OPIC”) as required under that certain Finance Agreement by and between OPIC and a subsidiary of Renergen and ENDRA’s having an amount of cash equal to or greater than $
The Merger Agreement may be terminated at any time prior to Closing by mutual written agreement between ENDRA and Noble or by either party if merger closing has not occurred by December 24, 2026. Either ENDRA or Noble may also terminate the Merger Agreement if the representations or warranties of the other party were inaccurate as of the date of the Merger Agreement or become inaccurate thereafter due to a breach of a covenant or agreement of that party prior to merger closing, or if the ENDRA Stockholder Matters are not approved by the ENDRA stockholders at the Special Meeting.
At or prior to the closing of the merger, the Company, ASPI South Africa Proprietary Limited, a wholly owned subsidiary of the Company (“ASPI SA”), and Renergen, shall enter into the sixth addendum to that certain ASPI Term Loan Facility, dated May 19, 2025, by and between the Company, ASPI SA and Renergen, pursuant to which the Company may provide loans to Renergen up to $
In connection with the Noble Investment, Noble entered into Subscription Agreements with certain of the Company’s directors and officers, pursuant to which Noble agreed to sell to those directors and officers Class A Units of Noble.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting segment exceeds its fair value.
The carrying amount of goodwill by reporting segment as of September 30, 2026 and December 31, 2025 is as follows (in thousands):
31
|
|
September 30, 2026 |
|
|
December 31, |
|
||
Specialist isotopes and related services |
|
$ |
|
|
$ |
|
||
Total goodwill |
|
$ |
|
|
$ |
|
||
The changes to the carrying value of goodwill, which is included in the isotopes and related services segment, is as follows:
Description |
|
Amount |
|
|
Balance as of December 31, 2025 |
|
$ |
|
|
Acquisition of Numed |
|
|
|
|
Translation adjustment |
|
|
|
|
Balance as of September 30, 2026 |
|
$ |
|
|
Intangible Assets
Amortization expense was $
The changes to the carrying value of intangible assets, which is included in the specialist isotopes and related services segments, is as follows (in thousands):
Description |
|
Amount |
|
|
Balance as of December 31, 2024 |
|
$ |
|
|
Trademarks from ECNP acquisition |
|
|
|
|
Amortization |
|
|
( |
) |
Balance as of December 31, 2025 |
|
$ |
|
|
Trademarks from Numed acquisition |
|
|
|
|
Amortization |
|
|
( |
) |
Balance as of September 30, 2026 |
|
$ |
|
|
The following table outlines the estimated future amortization expense related to intangible assets held as of September 30, 2026 (in thousands):
|
|
Amortization Expense |
|
|
Year Ended December 31, |
|
|
|
|
2026 |
|
$ |
|
|
2027 |
|
|
|
|
2028 |
|
|
|
|
2029 |
|
|
|
|
2030 |
|
|
|
|
Thereafter |
|
|
|
|
Total |
|
$ |
|
|
15. Equity Method and Other Investments
Investment in IsoBio, Inc.
On July 28, 2025, the Company purchased
As the owner of the Series Seed-1 Preferred Stock, the Company has the right to designate one board member. An officer and director of the Company was designated to fill that board seat. In addition, another board member of the Company is a board member, executive officer and shareholder of IsoBio.
The investment in IsoBio does not have a readily determinable fair value and is therefore measured at cost, adjusted for observable price changes and impairments, in accordance with ASC 321. As of September 30, 2026 and December 31, 2025, the carrying value of the investment was $
The Company monitors the investment for indicators of impairment and observable price changes on a quarterly basis. If indicators of impairment exist, the Company performs a qualitative assessment to determine whether the investment is impaired and adjusts the carrying value accordingly. Therefore, the Company has included this investment in the fair value hierarchy disclosure (Note 4). During the three and nine months ended September 30, 2026, the Company did
Skyline Investment
In August 2025, QLE entered into a Stock Purchase Agreement to purchase all
Effective as of March 29, 2026, QLE, entered into the Exchange Agreement with a third party investor in which the parties agreed to exchange
32
one-for-one basis. This resulted in QLE's voting rights in Skyline decreasing to under
Investment in Opeongo, Inc.
On January 26, 2026, the Company purchased
As the owner of the Series Seed-1 Preferred Stock, the Company has the right to designate one board member. An officer and director of the Company was designated to fill that board seat. In addition, another board member of the Company is a board member and shareholder of Opeongo.
The investment in Opeongo does
The Company monitors the investment for indicators of impairment and observable price changes on a quarterly basis. If indicators of impairment exist, the Company performs a qualitative assessment to determine whether the investment is impaired and adjusts the carrying value accordingly. During the three and nine months ended September 30, 2026, the Company did
ENDRA Life Sciences, Inc.
On May 27, 2026, the Company purchased
The investment in ENDRA is measured at fair value, adjusted for observable price changes and impairments, in accordance with ASC 321. As of September 30, 2026, the carrying value of the investment was $
The Company monitors the investment for indicators of impairment and observable price changes on a quarterly basis. If indicators of impairment exist, the Company performs a qualitative assessment to determine whether the investment is impaired and adjusts the carrying value accordingly. The Company recognized a gain from the change in fair value of investment of $
16. Stockholders’ Equity
Preferred stock
The Company has
Common stock
The Company has
In June 2025, the Company issued
In July 2025, the Company issued
In October 2025, the Company issued
In January 2026, the Company issued
In July 2026, the Company issued
Treasury shares are recorded at cost and include forfeited shares from the Company's stock compensation plans. There were
Common Stock Warrants
In May 2025, a warrant to purchase
33
17. Stock Compensation Plan
Equity Incentive Plans
In October 2021, the Company adopted the 2021 Stock Incentive Plan (“2021 Plan”) that provided for the issuance of common stock to employees, nonemployee directors, and consultants. Recipients of incentive stock options are eligible to purchase shares of common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2021 Plan provided for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock awards and stock appreciation rights. The maximum contractual term of options granted under the 2021 Plan is
In November 2022, the Company adopted the 2022 Equity Incentive Plan (“2022 Plan”) that provides for the issuance of common stock to employees, nonemployee directors, and consultants. Recipients of incentive stock options are eligible to purchase shares of common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2022 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock awards and stock appreciation rights. The maximum contractual term of options granted under the 2022 Plan is
2024 Inducement Equity Incentive Plan
In June 2024, the Company adopted the 2024 Inducement Equity Incentive Plan (“2024 Plan”). The 2024 Plan will be used exclusively for the grant of equity awards to individuals who were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4). Recipients of stock options are eligible to purchase shares of common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2024 Plan provides for the grant of non-statutory stock options, restricted stock, restricted stock units, stock awards and stock appreciation rights. The maximum contractual term of options granted under the 2024 Plan is
2025 Inducement Equity Incentive Plan
On July 16, 2025, upon recommendation of the Compensation Committee of the Company’s Board, the Board approved and adopted the Company’s 2025 Inducement Equity Incentive Plan (the “Inducement Equity Plan”), and subject to the adjustment provisions of the Inducement Equity Plan, reserved
The Inducement Equity Plan was approved and adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Equity Plan provides for grants of stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards (consisting of performance shares or performance units) and other cash-based or stock-based awards (each, an “Inducement Award”). In addition, the Board also approved and adopted forms of Notice of Grant of Restricted Stock and Restricted Stock Agreement, and Notice of Grant of Stock Option and Stock Option Agreement for use with the Inducement Equity Plan. The terms and conditions of the Inducement Equity Plan are intended to comply with the Nasdaq inducement award rules.
In accordance with Nasdaq Listing Rule 5635(c)(4), the only persons eligible to receive grants of Inducement Awards are individuals who were not previously employees or directors of the Company (or following a bona fide period of non-employment), as an inducement material to the individuals’ entry into employment with the Company. As of September 30, 2026,
QLE 2024 Equity Incentive Plan
In March 2024, the Company adopted the QLE 2024 Equity Incentive Plan (“QLE 2024 Plan”). The QLE 2024 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock awards, performance awards and stock appreciation rights to employees, nonemployee directors, and consultants. The maximum contractual term of options granted under the QLE 2024 Plan is
In September 2025, QLE granted restricted stock units (“RSUs”) totaling
Since the vesting of the RSUs is based on a liquidity event,
34
Stock Options
The following table sets forth the activity for the Company’s stock options during the periods presented:
|
|
Number of |
|
|
Weighted- |
|
|
Weighted |
|
|
Aggregate |
|
||||
Outstanding as of December 31, 2025 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Granted |
|
|
|
|
$ |
|
|
|
|
|
|
|
||||
Exercised |
|
|
( |
) |
|
$ |
|
|
|
|
|
|
|
|||
Forfeited |
|
|
( |
) |
|
$ |
|
|
|
|
|
|
|
|||
Outstanding as of September 30, 2026 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Exercisable as of September 30, 2026 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Vested or expected to vest as of September 30, 2026 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
The Company recorded stock-based compensation expense from options of $
Stock Awards
The Company recorded stock-based compensation expense from stock awards totaling $
The following table summarizes vesting of restricted common stock:
|
|
Number of |
|
|
Weighted |
|
||
Unvested as of December 31, 2025 |
|
|
|
|
$ |
|
||
Granted |
|
|
|
|
$ |
|
||
Vested |
|
|
( |
) |
|
$ |
|
|
Forfeited |
|
|
( |
) |
|
$ |
|
|
Unvested as of September 30, 2026 |
|
|
|
|
$ |
|
||
Stock-based Compensation Expense
Stock-based compensation expense for all stock awards recognized in the accompanying condensed consolidated statements of operations and comprehensive loss is as follows:
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Selling, general and administrative |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Research and development |
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|||
Total |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
18. Net Loss Per Share
The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of Common Stock after giving consideration to all potentially dilutive shares of common stock, including options to purchase common stock and warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential shares of Common Stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.
35
The following table sets forth the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2026 and 2025:
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss from continuing operations |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Income from discontinued operations |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Less: Net loss attributable to noncontrolling interests |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Net loss attributable to ASP Isotopes Inc. shareholders |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted average common stock outstanding, basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net (loss) income per share, basic and diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Continuing operations |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Discontinued operations |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Attributable to ASP Isotopes Inc. shareholders |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:
|
|
As of September 30, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Options to purchase common stock |
|
|
|
|
|
|
||
Restricted stock |
|
|
|
|
|
|
||
Warrants to purchase common stock |
|
|
|
|
|
|
||
Total shares of common stock equivalents |
|
|
|
|
|
|
||
19. Income Taxes
The Company’s effective tax rate for the three months ended September 30, 2026 and 2025 was -
The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition threshold to be recognized. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest and penalties on the Company’s balance sheets and has not recognized interest and/or penalties in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2026. Uncertain tax positions are evaluated based upon the facts and circumstances that exist at each reporting period. Subsequent changes in judgment based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustments may result, for example, upon resolution of an issue with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue. As of September 30, 2026 and December 31, 2025, there were no uncertain tax positions.
As of September 30, 2026, the Company did not recognize any interest and penalties associated with unrecognized tax benefits. Due to net operating losses incurred, tax years from inception remain open to examination by the Federal and State taxing jurisdictions to which the Company is subject. The Company is not currently under Internal Revenue Services (IRS), state or local tax examination.
Ownership changes, as defined in the Internal Revenue Code (“IRC”), may limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income pursuant to IRC Section 382 or similar provisions. Subsequent ownership changes could further affect the limitation in future years. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company’s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company’s ability to utilize net operating loss and research and development credit carryforwards in the future.
20. Related Party Transactions
PET Labs has an operating lease for office and production space in Pretoria, South Africa with monthly payment of about $
In connection with the Noble Investment, Noble entered into Subscription Agreements with certain of the Company’s directors and officers, pursuant to which Noble agreed to sell to those directors and officers Class A Units of Noble.
21. Discontinued Operations
Effective as of March 29, 2026, the Company entered into the Exchange Agreement and completed the deconsolidation of Skyline. The Company retained approximately
36
The following table presents the major categories of income from discontinued operations for the nine months ended September 30, 2026 (in thousands):
|
|
Nine Months Ended |
|
|
|
|
September 30, 2026 |
|
|
Gross profit |
|
$ |
|
|
Selling, general and administrative expenses |
|
|
( |
) |
Change in fair value of investments |
|
|
|
|
Other expenses, net |
|
|
( |
) |
Income from discontinued operations before income taxes |
|
|
|
|
Income tax expense |
|
|
( |
) |
Net income before allocation to noncontrolling interests |
|
|
|
|
Less: Net income attributable to noncontrolling interests |
|
|
|
|
Income from discontinued operations |
|
$ |
|
|
The following table presents the major classes of assets and liabilities of discontinued operations as of December 31, 2025 (in thousands):
|
|
December 31, |
|
|
Cash and cash equivalents |
|
$ |
|
|
Accounts receivable |
|
|
|
|
Prepaid and other current assets |
|
|
|
|
Total current assets of discontinued operations |
|
$ |
|
|
Property, plant and equipment, net |
|
|
|
|
Operating lease right-of-use lease assets |
|
|
|
|
Intangibles |
|
|
|
|
Goodwill |
|
|
|
|
Equity investments |
|
|
|
|
Other investments |
|
|
|
|
Other noncurrent assets |
|
|
|
|
Total non-current assets of discontinued operations |
|
|
|
|
Total assets of discontinued operations |
|
$ |
|
|
Accounts payable |
|
|
|
|
Accrued expenses |
|
|
|
|
Notes payable -current |
|
|
|
|
Operating lease liabilities - current |
|
|
|
|
Due to related parties |
|
|
|
|
Other current liabilities |
|
|
|
|
Total current liabilities of discontinued operations |
|
|
|
|
Deferred Tax Liabilities |
|
|
|
|
Total non-current liabilities of discontinued operations |
|
|
|
|
Total liabilities of discontinued operations |
|
$ |
|
|
|
|
Nine Months Ended |
|
|
|
|
September 30, 2026 |
|
|
Net cash used in operating activities |
|
$ |
( |
) |
Net cash provided by financing activities |
|
$ |
|
|
The total net impact to stockholders' equity as a result of the separation was a reduction of $
22. Subsequent Events
The Company has evaluated subsequent events through November 16, 2026, the date on which the accompanying condensed consolidated financial statements were issued and concluded that no subsequent events have occurred that require disclosure except as described below.
First Amendment to Merger Agreement. As previously disclosed, on June 25, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among ENDRA Life Sciences Inc., a Delaware corporation (“ENDRA”), Noble Africa LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of the Company (“Noble”), Renergen and Kruger Merger Sub LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of ENDRA (“Merger Sub”), pursuant to which Merger Sub will merge with and into Noble (the “Merger”), with Noble surviving the Merger as a direct wholly-owned subsidiary of ENDRA.
On October 1, 2026, the Company, ENDRA, Noble, Renergen and Merger Sub entered into that certain First Amendment to the Merger Agreement (the “Amendment”) to, among other things, (i) amend ENDRA’s disclosure letter to permit ENDRA to amend the Pre-Funded Common Stock Purchase Warrant (the “Pre-Funded Warrant”) and Common Stock Purchase Warrant (the “Common
37
Warrant” and, together with the Pre-Funded Warrant, the “Warrants”), each issued by ENDRA as of May 27, 2026 to LHE LNG Holdings LLC, a direct, wholly-owned subsidiary of the Company (the “ASPI ENDRA Purchaser”), (ii) remove the requirement that the board of directors immediately following the closing of the Merger be classified into three separate classes, (iii) revise the minimum cash closing condition to reflect a minimum cash requirement of $
38
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on April 10, 2026 and Amendment No. 1 to our Annual Report on Form 10-K/A filed with the SEC on April 30, 2026 (as amended, the “Annual Report”), along with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Annual Report. The Annual Report is accessible on the SEC’s website at www.sec.gov and on our website at www.aspisotopes.com. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled “Risk Factors” in the Annual Report and this Quarterly Report on Form 10-Q, and the section entitled “Special Note Regarding Forward-Looking Statements” above, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the section entitled “Risk Factors” in the Annual Report and this Quarterly Report on Form 10-Q, and the section entitled “Special Note Regarding Forward-Looking Statements” above to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements.
Overview
We are an advanced materials company dedicated to the development of a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. Our proprietary enrichment technologies, the Aerodynamic Separation Process (“ASP technology”) and QE technology, are designed to enable the production of isotopes for a range of industrial and advanced technology applications. Our initial focus is on the production and commercialization of enriched Carbon-14 (“C-14”), Silicon-28 (“Si-28”) and Ytterbium-176 (“Yb-176”). Our commercial radiodiagnostic activities are currently focused on radiopharmaceutical products used in positron emission tomography ("PET") and single-photon emission computed tomography ("SPECT") imaging, as well as therapeutic radiopharmaceuticals used in the treatment of oncology indications.
We commenced commercial production of enriched isotopes at both of our ASP enrichment facilities located in Pretoria, South Africa during the first half of 2025. However, we have not generated any revenue from the sale of our enriched isotopes as of September 30, 2026. Our first ASP enrichment facility is designed to enrich light isotopes, such as C-14 and C-12. The second ASP enrichment facility, which is substantially larger than the first, should have the potential to enrich kilogram quantities of relatively heavier isotopes, including but not limited to Si-28. Depending on the timing and the quality of the feedstock received from our customer, our initial shipments of enriched C-14 may occur in 2027. We are targeting initial shipments of enriched Si-28 in the fourth quarter of 2026. We have also completed the commissioning phase of our third enrichment facility, a QE technology facility, which is our first laser-based enrichment plant. We are targeting initial shipments of Yb-176 in 2027.
In addition, we have started planning additional isotope enrichment plants both in South Africa and in other jurisdictions, including Iceland and the United States. We believe the C-14 we may produce using the ASP technology could be used in the development of new pharmaceuticals and agrochemicals. We believe the Si-28 we may produce using the ASP technology may be used to create advanced semiconductors and in quantum computing. We believe the Yb-176 we may produce using the QE technology may be used to create radiotherapeutics that treat various forms of oncology. We are considering the future development of the ASP technology for the separation of Zinc-68 and Xenon-129/136 for potential use in the healthcare end market, Germanium 70/72/74 for potential use in the semiconductor end market, and Chlorine -37 for potential use in the nuclear energy end market. We are also considering the future development of QE technology for the separation of Nickel-64, Gadolinium-160, Ytterbium-171, Lithium-6 and Lithium-7.
QLE, our subsidiary, is currently pursuing an initiative to apply our enrichment technologies to the enrichment of Uranium-235 (“U-235”) in South Africa. We believe that the U-235 QLE may produce has the potential to be commercialized as a nuclear fuel component for use in the new generation of high-assay low-enriched uranium (“HALEU”)-fueled small modular reactors that are now under development for commercial and government uses. In furtherance of our uranium enrichment initiative in South Africa, we have entered into certain definitive agreements with TerraPower, LLC (“TerraPower”), including a term loan subject to conditions to support construction of a new uranium enrichment facility at Pelindaba, South Africa and supply agreements for the future supply of HALEU to TerraPower, as a customer. In addition, QLE’s South African subsidiary has entered into a Pre-Implementation Services Contract Agreement (“Services Contract”) with The South African Nuclear Energy Corporation (“Necsa”), a South African state-owned company responsible for undertaking and promoting research and development in the field of nuclear energy and radiation sciences, pursuant to which Necsa has agreed to provide to QLE’s South African subsidiary certain facilities, infrastructure, utilities and services related to the siting, design, construction, commission and operation of an enrichment facility on the Necsa site in Pelindaba. In the period since our inception to date, we have not applied our enrichment technologies to the enrichment of U-235, nor received permission or regulatory approval to conduct testing of our enrichment technologies on U-235, except for the activities contemplated by the Services Contract with Necsa. Our expectation that QLE’s initiative to apply our enrichment technologies to the enrichment of U-235 could be successful is based upon research conducted by certain of our scientists prior to joining us, as well as the demonstrated effectiveness of QE technology on Yb-176.
We acquired Renergen in January 2026 and issued 14,270,000 Consideration Shares in connection with this acquisition. Renergen is South Africa’s leading onshore natural gas explorer and the first integrated producer of both liquid helium and LNG, both of which are produced from the natural gas reserve base that underpins Renergen’s Virginia Gas Project. The Virginia Gas Project includes (i) the liquefaction of natural gas into LNG, (ii) the separation of helium from natural gas, and (iii) the further liquefaction of helium into 99.999% pure liquid helium. This liquefaction and separation takes place at Renergen’s Virginia Gas Plant. Renergen’s principal asset is its 94.5% equity ownership in Tetra4, which holds an onshore petroleum production right and is the entity developing the Virginia Gas Project.
QLE entered into the Securities Exchange Agreement with a third party, effective as of March 29, 2026, which resulted in the deconsolidation of Skyline (Note 21). QLE retained approximately 8.6% percent of the outstanding Class A ordinary and preferred shares of Skyline immediately following deconsolidation.
39
Our Subsidiaries and Segments
We operate our proprietary enrichment activities principally through our subsidiaries. ASP Isotopes Guernsey Limited (the holding company for our subsidiaries in the Cayman Islands, South Africa, Iceland and the United Kingdom) is focused on the development and commercialization of high-value, low-volume isotopes for highly specialized end markets (such as C-14, Si-28, and Yb-176). ASP Isotopes UK Ltd is the owner of our technology.
QLE. In September 2023, we formed QLE, which also has subsidiaries in the United Kingdom (Quantum Leap Energy Limited) and South Africa (Quantum Leap Energy (Pty) Limited), to focus on the development and commercialization of advanced nuclear fuels, such as HALEU and Lithium-6. QLE’s direct wholly owned subsidiary QLE UK, has its operations in the United Kingdom. QLE UK’s direct wholly owned subsidiary, QLE South Africa, has its operations in South Africa. QLE also formed QLE SPE Borrower, as a wholly owned subsidiary to act as a special purpose borrower for a loan transaction with TerraPower, a US nuclear innovation company. The QLE SPE Borrower has formed a subsidiary in South Africa to act as the project company for a proposed new uranium enrichment facility at Pelindaba, South Africa.
QLE’s mission is to address perceived gaps in the nuclear fuel cycle, promote safe nuclear power, and enhance the sustainability of the nuclear fuel cycle for advanced nuclear reactors and fusion systems, as well as the existing nuclear fleet. We believe that many advanced nuclear reactors, including SMRs, will rely on fuels with higher uranium enrichment levels, specifically HALEU, which we intend to produce. QLE also intends to produce high-isotopic purity fuel feedstock, such as Lithium-6, for fusion reactors, and by extension, Lithium-7 for Light Water Reactor control. These fuels may enable greater efficiency, compact reactor footprints, and lengthened operational cycles between refueling. Given the flexible nature of our enrichment technology and integrated value chain approach, QLE also intends to make available LEU+ to the existing fleet of nuclear reactors currently running on LEU, thus enabling existing reactors to lengthen the time between refueling, cut costs and boost power output.
As previously announced, our board of directors intends to pursue the separation of our Nuclear Fuels business and Specialist Isotopes and Related Services business into two independent companies. The regulatory landscape and supply chain for nuclear fuel production differs significantly from that of medical isotopes, hence we and QLE have different business models and we believe that both companies would benefit if QLE is independently managed and financed. We plan to effect the separation through a listing of QLE in a transaction that results in QLE existing as a separate public company with shares listed on a U.S. national securities exchange and a portion of QLE’s common equity being distributed to our stockholders as of a to-be-determined future record date. While we currently believe that a listing of QLE as a separate public company is the most likely separation transaction, our board of directors remains committed to maximizing shareholder value creation, and will continue to evaluate other options for separation to maximize shareholder value.
We entered into a number of agreements with QLE, including a License Agreement, pursuant to which QLE has licensed from us the rights to technologies and methods used to separate U-235 and Lithium-6 (including but not limited to the QE and ASP technologies) in exchange for a perpetual royalty in the amount of 10% of all future QLE revenues, and an EPC Services Framework Agreement, pursuant to which we will provide services for the engineering, procurement and construction of one or more turnkey U-235 and Lithium-6 enrichment facilities in locations to be identified by QLE and owned or leased by QLE, and commissioning, start-up and test services for each such facility, subject to the receipt of all applicable regulatory approvals, permits, licenses, authorizations, registrations, certificates, consents, orders, variances and similar rights.
PET Labs. We have a 51% ownership stake in PET Labs, a South African radiopharmaceutical operations company focused on the production of fluorinated radioisotopes and active pharmaceutical ingredients, through which we entered the downstream medical isotope production and distribution market. Under the terms of the Share Purchase Agreement pursuant to which we acquired the shares in PET Labs, we agreed to pay a total of $2.0 million for the shares in two installments, which has been paid in full as of December 2025. In addition, we have an option to purchase the remaining 49% of the outstanding equity in PET Labs, exercisable until January 31, 2027, for $2.2 million.
East Coast Nuclear Pharmacy. In October 2025, we completed the acquisition of East Coast Nuclear Pharmacy ("ECNP"). Pursuant to the terms of the agreement, we acquired 100% of the issued and outstanding membership interests for total purchase consideration of $2.5 million of which $2.0 million was paid up front in cash and the remaining $0.5 million was deferred through the issuance of notes payable that were repaid in June 2026.
Numed Diagnostics, LLC ("Numed"). In January 2026, we acquired 60% of the issued and outstanding membership interests of Numed for $0.8 million. Numed is an independent radiopharmacy dedicated to nuclear medicine and the science of radiopharmaceutical production. In addition to the purchase consideration, we have an option to purchase the remaining 40% of the issued and outstanding membership interests within two years following the closing for an agreed consideration totaling $0.5 million.
Renergen Acquisition. On January 6, 2026, we acquired all of the issued and outstanding Renergen ordinary shares from Renergen shareholders in exchange for shares of our common stock through the implementation of the Scheme in accordance with Sections 114 and 115 of the South African Companies Act, No. 71 of 2008, resulting in the issuance of an aggregate of 14,270,000 shares of our common stock. As a result of the transactions contemplated by the Scheme, the Renergen ordinary shares, which were publicly traded on the Johannesburg Stock Exchange (JSE: REN) and the Australian Securities Exchange (ASX:RLT), were delisted and Renergen became a wholly owned subsidiary of ASP Isotopes.
Renergen is South Africa’s leading onshore natural gas explorer and the first integrated producer of both liquid helium and LNG, both of which are produced from the large natural gas reserve base that underpins Renergen’s Virginia Gas Project. The Virginia Gas Project includes (i) the liquefaction of natural gas into LNG, (ii) the separation of helium from natural gas, and (iii) the further liquefaction of helium into 99.999% pure liquid helium. This liquefaction and separation takes place at Renergen’s Virginia Gas Plant in the Free State Province of South Africa. Based on the drilled and flow-tested wells, Renergen’s average helium concentration exceeds 3.0%, which is well above typical conventional natural gas reservoirs containing helium in small concentrations (less than 0.5%).
Renergen’s principal asset is its 94.5% equity ownership in Tetra4, which holds South Africa’s first and only onshore petroleum Production Right and is the entity developing the Virginia Gas Project. Phase 1 of the Virginia Gas Project has commenced commercial LNG operations. The Virginia Gas Project benefits from favorable supply and demand trends in both the LNG and liquid helium sectors. The LNG is and will continue to be sold domestically in South Africa into a market suffering energy and natural gas shortages, and we
40
plan to sell helium directly to global customers at a time when the world is suffering helium supply shortages, which have been further exacerbated by the ongoing United States-Israel-Iran conflict and associated disruptions to shipping through the Strait of Hormuz. The global helium supply chain has been materially disrupted by these geopolitical developments, with repairs to affected production infrastructure expected to take years rather than months. In addition, in April 2026, Russia introduced export controls on helium to maintain domestic supply, further constraining global availability. We believe that the U.S. International Development Finance Corporation (“DFC”) previously indicated its willingness to consider supporting the funding of Phase 2 of the Virginia Gas Project for up to $500 million as part of the U.S.’s initiative to ensure new helium supply comes online as aerospace and the semiconductor industry increase helium requirements in the face of diminished supply, while increasing South Africa’s domestic energy supply.
Helium is a vital and irreplaceable element in many modern industries because it is both chemically and electrically inert and, when in liquid form, is the coldest substance known to man at 4 degrees Kelvin (minus 454.3 degrees Fahrenheit). For these reasons, it can be used in the manufacture of semiconductors, to purge laboratory or manufacturing environments, act as a fuel propellant for other cryogenic fuels, and/or provide deep cryogenic cooling. It is commonly used in space exploration and rocketry, high-level physics experiments (e.g., particle accelerators, quantum mechanics), medical science within MRI devices, fiber optic cable production, commercial diving gas, specialized welding, coolant for nuclear power stations and lifting balloons.
We believe that Renergen’s LNG supply can play an important role in reducing South Africa's relatively high carbon emissions by being the first, and currently the only, LNG supplier in the country. According to Energy Institute (2024), coal has a 69% share of national primary energy consumption, with gas only around 3.5%. As such, according to the World Bank, South Africa ranks as the fifth-worst carbon emissions country per kilogram per purchasing power parity of gross domestic product (“GDP”). This ranking is largely due to South Africa’s high reliance on low-grade coal to provide electricity, supplemented by Sasol’s use of coal to liquids technology. Sasol Limited is one of the country’s largest energy suppliers and operator of the natural gas pipeline supplying gas from Mozambique into Johannesburg. LNG is a significantly lower carbon-emitting fuel than either of coal (by 50%) and diesel (25%), upon combustion. Therefore, the introduction of Renergen’s LNG into South Africa’s energy supply mix, including the possible direct substitution of Renergen’s LNG for first diesel, and then potentially coal, may help reduce South Africa’s overall carbon emissions intensity as the country moves towards its net zero carbon emissions targets by 2050.
Mahlako Gas Energy Limited (“MGE”) has a 5.5% equity ownership in Tetra4. MGE, Renergen and Tetra are parties to a Sale, Subscription and Shareholders’ Agreement, dated December 22, 2023 (the “SSSA”), pursuant to which MGE acquired its equity in Tetra4 for ZAR 550 million. Under the SSSA, Renergen granted to MGE a put option related to MGE's equity (the “Put Option”) exercisable upon the occurrence of a Put Option Event (as defined in the SSSA). The price payable for MGE’s equity under the Put Option is calculated pursuant to a formula set forth in the SSSA, but will be not less than the aggregate of (i) the purchase price of MGE's equity paid by MGE (ZAR 550 million) plus the face value of any claims, (ii) 3.5% of such purchase price, and (iii) MGE's documented due diligence costs.
Investments in Early Stage Drug Development Companies
IsoBio. On July 28, 2025, we purchased 2,000,000 shares of IsoBio Series Seed-1 Preferred Stock at $2.50 per share for a total aggregate purchase price of $5.0 million. IsoBio is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. As the owner of the Series Seed-1 Preferred Stock, we have the right to designate one board member. An officer and director of ours was designated to fill that board seat. In addition, another board member of ours is a board member and executive officer of IsoBio.
Opeongo. On January 26, 2026, we purchased 4,356,918 shares of Opeongo Series Seed-1 Preferred Stock at $2.2952 per share for a total aggregate purchase price of $10.0 million. Opeongo is a biotechnology company developing novel therapeutics using extracellular matrix modulation to target fibrosis, inflammation, and cancer. Opeongo was co-founded by David Baram, Ph.D. who serves as Opeongo’s Chief Executive Officer and director. As the owner of the Series Seed-1 Preferred Stock, we have the right to designate one board member. An officer and director of ours was designated to fill that board seat. In addition, another board member of ours is a board member and executive officer of Opeongo.
ENDRA. On May 27, 2026, we purchased 66,846 shares of ENDRA common stock, 511,541 prefunded warrants to purchase shares of common stock and 1,156,774 common warrants to purchase shares of common stock for a total aggregate purchase price of $3.8 million. ENDRA is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), a technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care.
Agreements with TerraPower LLC
On April 4, 2024, we entered into the TerraPower Agreement with TerraPower to develop a conceptual design, refined cost/schedule/financing, risk register, and term sheet for a HALEU facility. The TerraPower Agreement may be terminated for (a) breach or default, (b) our convenience or (c) TerraPower’s convenience. TerraPower is obligated to make all payments for milestones completed by us and these payments are nonrefundable.
On October 18, 2024, we signed the TerraPower Term Sheet that provides for the execution of two definitive agreements: (1) an agreement pursuant to which TerraPower will provide funding for our construction of a uranium enrichment facility capable of producing HALEU using our proprietary aerodynamic separation process technology to be located in the Republic of South Africa and (2) An agreement pursuant to which we will deliver to TerraPower the full capacity of the enrichment facility.
In May 2025, we entered into the TerraPower Loan Agreement, which provides conditional commitments from TerraPower to us through one of our wholly-owned U.S.-based subsidiaries for a multiple advance term loan totaling $22.0 million for the purpose of partially funding the construction of a proposed new uranium enrichment facility in South Africa. The total loan amount is inclusive of a 10% original issue discount on each disbursement and carries a fixed interest rate of 10% per annum. Per the terms of the TerraPower Loan Agreement and subject to the satisfaction of various conditions precedent to disbursements (including receiving all required licenses and permits to perform uranium enrichment in South Africa), we will receive aggregate loan disbursements of $20.0 million. Such loan matures on May 16, 2032. Interest will begin accruing upon each milestone disbursement we receive and will be added to the principal balance until November 2027. Principal and interest payments will be made in 60 equal installments beginning in November 2027.
41
In addition to the TerraPower Loan Agreement, in May 2025, we and TerraPower have entered into two supply agreements for the HALEU expected to be produced at our uranium enrichment facility. The initial core supply agreement is intended to support the supply of the required first fuel cores for the initial loading of TerraPower’s Natrium project in Wyoming. The long-term supply agreement is a 10-year supply agreement of up to a total of 150 metric tons of HALEU, commencing in 2028 through end of 2037.
Financings and Other Transactions
In June 2025, we issued 7,518,797 shares of common stock at $6.65 per share in a registered direct offering resulting in net proceeds of approximately $46.8 million after deducting underwriting discounts, commissions and offering expenses.
In July 2025, we issued 7,500,000 shares of common stock at $8.00 per share in a registered direct offering resulting in net proceeds of approximately $56.3 million after deducting underwriting discounts, commissions and offering expenses.
In October 2025, we issued 17,167,380 shares of common stock in a registered offering at the offering price of $12.25 per share, for net proceeds of approximately $199.3 million, after deducting underwriting discounts and commissions and estimated offering expenses.
On November 19, 2025, QLE received gross proceeds of $72.2 million through the issuance of convertible promissory notes with a stated interest rate of 8% (the “2025 Convertible Notes”), including $30.0 million in gross proceeds from ASP Isotopes, its parent. The maturity date of the 2025 Convertible Notes is November 19, 2030. The 2025 Convertible Notes automatically convert into common shares upon QLE’s closing of an IPO or other qualifying public transaction at 80% of the share price taking into consideration a valuation cap. In connection with the issuance of the 2025 Convertible Notes, QLE’s outstanding convertible promissory notes originally issued in March 2024 and June 2024 automatically converted into 2025 Convertible Notes with a value of $147.7 million.
On January 6, 2026, we issued 14,270,000 Consideration Shares in connection with the acquisition of Renergen.
On March 29, 2026, QLE, entered into an Exchange Agreement with a third party investor in which the parties agreed to exchange 1,995,000 Class B common shares owned by QLE for 1,995,000 Class A shares owned by the third party investor, on a one-for-one basis. This resulted in QLE's ownership in Skyline decreasing to under 10%.
On July 15, 2026, we and QLE entered into separate, individually negotiated private securities exchange agreements with certain holders of the 2025 Convertible Notes, pursuant to which such noteholders exchanged approximately $109.2 million in aggregate principal amount of the outstanding 2025 Convertible Notes, plus accrued and unpaid interest thereon, for an aggregate of 23,160,682 shares of our common stock (the “Exchange Transactions”). The Exchange Transactions closed on July 16, 2026. Upon the closing of the Exchange Transactions, the outstanding principal amount of 2025 Convertible Notes held by third party investors was reduced to approximately $80.6 million. ASP Isotopes holds approximately $139.2 million aggregate principal amount of 2025 Convertible Notes, which are eliminated in consolidation.
ENDRA Merger Agreement and Noble Private Placement
Merger Agreement. On June 25, 2026, we entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among ENDRA, Noble Africa LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of us (“Noble”), Renergen, ASP Isotopes, and Kruger Merger Sub LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of ENDRA (“Merger Sub”), pursuant to which Merger Sub will merge with and into Noble (the “Merger”), with Noble surviving the Merger as a direct wholly-owned subsidiary of ENDRA. Prior to the effective time of the Merger, we will contribute all of our equity interest in Renergen to Noble in exchange for 55,500,000 of Noble’s Class B Units. The shares of Class B common stock received by the Company upon conversion of the Class B Units in connection with the Merger will entitle the Company to 10 votes per share on all matters submitted to a vote of the stockholders of ENDRA. Following the Merger, ENDRA will be renamed “4K Resources, Inc.” and its Class A common stock is expected to be listed on Nasdaq.
Noble Private Placement. Concurrently with the entry into the Merger Agreement, Noble entered into subscription agreements with us and certain investors pursuant to which Noble agreed to sell approximately (i) 4,594,218 Class A Units of Noble and/or pre-funded warrants to purchase Class A Units of Noble to certain institutional investors and other persons and (ii) 3,054,185 Class B Units of Noble to us, at a price per unit of $6.57, for aggregate gross proceeds to Noble of approximately $50 million (the “Noble Investment”). The Noble Investment is expected to close immediately prior to the Merger.
Merger Agreement Amendment. On October 1, 2026, the Company, ENDRA, Noble, Renergen and Merger Sub entered into that certain First Amendment to the Merger Agreement (the “Amendment”) to, among other things, (i) amend ENDRA’s disclosure letter to permit ENDRA to amend the Pre-Funded Common Stock Purchase Warrant (the “Pre-Funded Warrant”) and Common Stock Purchase Warrant (the “Common Warrant” and, together with the Pre-Funded Warrant, the “Warrants”), each issued by ENDRA as of May 27, 2026 to LHE LNG Holdings LLC, a direct, wholly-owned subsidiary of the Company (the “ASPI ENDRA Purchaser”), as further described below, (ii) remove the requirement that the board of directors immediately following the closing of the Merger be classified into three separate classes, (iii) revise the minimum cash closing condition to reflect a minimum cash requirement of $3,800,002.59, less certain agreed-upon expenses to permit ENDRA to engage in certain investor relations activities, (iv) replace the form of ENDRA’s Fifth Amended and Restated Certificate of Incorporation with an updated form that removes the classified board provisions and other provisions that would have required a supermajority vote of ENDRA’s stockholders to be approved, (v) amend Noble Africa’s disclosure letter to permit Renergen to enter into a fifth addendum to that certain Term Loan Facility Agreement, dated as of May 19, 2025, by and between Renergen, ASPI and ASPI South Africa Proprietary Limited, a wholly-owned subsidiary of ASPI (the “ASPI Term Loan Facility”), which would increase Renergen’s borrowing capacity from ASPI from $80 million to up to $120 million and (vi) contemplate a sixth addendum to the ASPI Term Loan Facility to be entered into at or prior to the closing of the Merger, which would further increase Renergen’s borrowing capacity from ASPI from $120 million to up to $200 million. Except as expressly modified by the Amendment, the terms of the Merger Agreement were ratified and remain in full force and effect.
ENDRA Investment. On May 27, 2026, ENDRA entered into a securities purchase agreement (the “Securities Purchase Agreement”) with the ASPI ENDRA Purchaser pursuant to which ENDRA agreed to sell and issue to the ASPI ENDRA Purchaser in a private placement offering an aggregate of 66,846 shares of ENDRA common stock, par value $0.0001 per share (the “ENDRA Common Stock”), Pre-Funded Warrants to purchase an aggregate of up to 511,541 shares of ENDRA Common Stock (the “Pre-Funded Warrant Shares”) at a per share exercise price of $0.0001 and Common Warrants to purchase an aggregate of up to 1,156,774 shares of ENDRA Common Stock (the “Common Warrant Shares” and together with the Pre-Funded Warrant Shares, the “Warrant Shares”)) at a per share exercise price of $6.57. On October 1, 2026, ENDRA and the ASPI ENDRA Purchaser entered into (i) Amendment No. 1 to Common
42
Stock Purchase Warrant (the “Common Warrant Amendment”) and (ii) Amendment No. 1 to Pre-Funded Common Stock Purchase Warrant (the “Pre-Funded Warrant Amendment” and, together with the Common Warrant Amendment, the “Warrant Amendments”). The Warrant Amendments make changes to each Warrant to, among other things, remove the 4.99% beneficial ownership limitation on the ASPI ENDRA Purchaser’s ability to exercise each Warrant. Except as amended by the Warrant Amendments, the terms of each Warrant remain unaltered and in full force and effect. As previously disclosed, a portion of the Pre-Funded Warrants in respect of 324,372 Pre-Funded Warrant Shares and all of the Common Warrants will only become exercisable upon ENDRA obtaining stockholder approval of the issuance of such Pre-Funded Warrant Shares and Common Warrant Shares.
Closing of the Merger. In connection with the Merger, ENDRA filed a Registration Statement on Form S-4 (File No. 333-299256) (the "Registration Statement") with the SEC on October 2, 2026. We refer you to the disclosures in the proxy statement/prospectus (which is preliminary and subject to completion) that is included in the Registration Statement for additional information relating to the Merger and ENDRA. Consummation of the Merger is subject to certain closing conditions, including the approval by ENDRA’s stockholders, the effectiveness of the Registration Statement, the approval for listing of the Class A Common Stock on Nasdaq, ENDRA having an amount of cash equal to or greater than $3.8 million, the receipt by Noble of the proceeds of the Noble Investment, we having contributed our equity interests in Renergen to Noble, and Noble’s receipt of a written consent of the U.S. International Development Finance Corporation as required under the finance agreement with Tetra4. The Merger Agreement may be terminated by either party if the Merger has not been completed by December 24, 2026. The Merger is anticipated to close in the fourth quarter of 2026 or, subject to the parties’ agreement to extend the outside date for consummating the Merger, the first quarter of 2027.
Other Contractual Obligations
We enter into contracts in the normal course of business for testing, manufacturing and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice. For additional details regarding our contractual obligations, see Note 11 "Commitments and Contingencies" and Note 12 “Leases” to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.
Components of Results of Operations
Revenue
We recognize product revenue from the sale of nuclear medical doses for PET scanning. Beginning in the fourth quarter of 2025, we started recognizing product revenue from the sale of nuclear medical doses for SPECT scanning. Effective with the acquisition of 100% of Renergen in the first quarter of 2026, we started recognizing product revenue from the sale of LNG. We also recognize collaboration revenue from our TerraPower R&D Agreement.
Cost of Revenue
Cost of revenue associated with the sale of nuclear medical doses for PET and SPECT scanning and the sale of LNG consist of labor, processing costs, delivery and materials. There is no cost of revenue associated with our collaboration revenue.
Operating Expenses
Our operating expenses consist of (i) research and development expenses and (ii) selling, general and administrative expenses.
Research and Development
Our research and development expenses consist primarily of direct and indirect costs incurred in connection with the development activities for our future isotopes.
Direct costs include:
Indirect costs include:
Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.
We expect that our research and development expenses will increase substantially for the foreseeable future as we continue the development of our future isotopes. We cannot determine with certainty the timing of initiation, the duration or the completion costs of development activities. Actual development timelines, the probability of success and development costs can differ materially from expectations.
We will need to raise substantial additional capital in the future. In addition, we cannot forecast which future isotopes may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.
Our research and development expenses may vary significantly based on a variety of factors, such as:
43
A change in the outcome of any of these variables with respect to the development of any of our future isotopes could significantly change the costs and timing associated with the development of that future isotope.
Selling, General and Administrative
Selling, general and administrative expenses consist primarily of personnel-related costs, which include salaries, payroll taxes, employee benefits, and other employee-related costs, including stock-based compensation expense, for personnel in executive, sales, finance and other administrative functions. Other significant costs include legal fees relating to corporate matters, professional fees for accounting and consulting services and facility-related costs.
We expect that our ongoing selling, general and administrative expenses will increase substantially for the foreseeable future to support our increased research and development activities and increased costs of operating as a public company and in building our internal resources. These increased costs will include increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor and public relations costs associated with operating as a public company.
Segment Information
Beginning in 2024, primarily as a result of increased business activities of our subsidiary, QLE, we had two operating segments: (i) nuclear fuels, and (ii) specialist isotopes and related services. Beginning in August 2025, primarily as a result of the acquisition of Skyline, we had three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Beginning in the first quarter of 2026, primarily as a result of the acquisition of Renergen and the deconsolidation of Skyline, we have three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) Helium and LNG. Our prior “construction services” segment is shown below as “discontinued operations” due to the deconsolidation of Skyline.
The specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Si-28 and Yb-176) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging and semiconductors, as well as services related to these isotopes, and this segment includes operations of PET Labs, Numed, and ECNP.
The nuclear fuels segment is focused on research and development of technologies and methods used to produce HALEU and Lithium-6 for the advanced nuclear fuels target end market, and this segment includes operations of QLE.
The Helium and LNG segment is focused on the exploration, production and sale of LNG in South Africa, and this segment includes operations of Renergen.
The financial information is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources. Our CODM is our chief executive officer. The CODM regularly reviews any asset information by operating segment and, accordingly, asset information is reported on a segment basis.
The following table shows total assets by segment and a reconciliation to the condensed consolidated financial statements as of September 30, 2026 and December 31, 2025 (in thousands):
|
|
September 30, |
|
|
December 31, |
|
||
Segment assets: |
|
|
|
|
|
|
||
Specialist isotopes and related services |
|
$ |
210,920 |
|
|
$ |
321,190 |
|
Nuclear fuels |
|
|
96,707 |
|
|
|
94,252 |
|
Helium and LNG |
|
|
230,502 |
|
|
|
— |
|
Discontinued operations |
|
|
— |
|
|
|
82,578 |
|
Total assets |
|
$ |
538,129 |
|
|
$ |
498,020 |
|
Select information from the condensed consolidated statements of operations and comprehensive loss as of the three months ended September 30, 2026 and 2025 is as follows:
|
|
Revenues |
|
|
Segment Operating Loss |
|
||||||||||
|
|
Three Months Ended September 30, |
|
|
Three Months Ended September 30, |
|
||||||||||
Segment |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Specialist isotopes and related services |
|
$ |
4,257 |
|
|
$ |
1,271 |
|
|
$ |
(18,630 |
) |
|
$ |
(11,763 |
) |
Nuclear fuels |
|
|
— |
|
|
|
— |
|
|
|
(11,466 |
) |
|
|
(3,224 |
) |
Helium and LNG |
|
|
867 |
|
|
|
— |
|
|
|
(10,419 |
) |
|
|
— |
|
|
|
$ |
5,124 |
|
|
$ |
1,271 |
|
|
$ |
(40,515 |
) |
|
$ |
(14,987 |
) |
Select information from the condensed consolidated statements of operations and comprehensive loss as of the nine months ended September 30, 2026 and 2025 is as follows:
|
|
Revenues |
|
|
Segment Operating Loss |
|
||||||||||
|
|
Nine Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
Segment |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Specialist isotopes and related services |
|
$ |
11,512 |
|
|
$ |
3,571 |
|
|
$ |
(50,094 |
) |
|
$ |
(27,218 |
) |
Nuclear fuels |
|
|
800 |
|
|
|
— |
|
|
|
(29,288 |
) |
|
|
(7,690 |
) |
Helium and LNG |
|
|
2,115 |
|
|
|
— |
|
|
|
(20,216 |
) |
|
|
— |
|
|
|
$ |
14,427 |
|
|
$ |
3,571 |
|
|
$ |
(99,598 |
) |
|
$ |
(34,908 |
) |
44
Results of Operations
Comparison of the Three Months Ended September 30, 2026 and 2025
The following table summarizes our results of operations for the three months ended September 30, 2026 and 2025:
|
|
Three Months Ended September 30, |
|
|
|
|
||||||
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|||
Product revenue |
|
$ |
5,124 |
|
|
$ |
1,271 |
|
|
$ |
3,853 |
|
Total revenue |
|
|
5,124 |
|
|
|
1,271 |
|
|
|
3,853 |
|
Cost of revenue |
|
|
4,331 |
|
|
|
1,029 |
|
|
|
3,302 |
|
Gross profit |
|
|
793 |
|
|
|
242 |
|
|
|
551 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|||
Research and development |
|
|
7,236 |
|
|
|
3,098 |
|
|
|
4,138 |
|
Selling, general and administrative |
|
|
34,072 |
|
|
|
12,131 |
|
|
|
21,941 |
|
Total operating expenses |
|
|
41,308 |
|
|
|
15,229 |
|
|
|
26,079 |
|
Other (expense) income: |
|
|
|
|
|
|
|
|
|
|||
Foreign exchange transaction loss |
|
|
(511 |
) |
|
|
(15 |
) |
|
|
(496 |
) |
Change in fair value of share liability |
|
|
— |
|
|
|
(71 |
) |
|
|
71 |
|
Change in fair value of convertible notes payable |
|
|
164 |
|
|
|
173 |
|
|
|
(9 |
) |
Change in fair value of investments |
|
|
(988 |
) |
|
|
— |
|
|
|
(988 |
) |
Gain on extinguishment of convertible notes |
|
|
11,250 |
|
|
|
— |
|
|
|
11,250 |
|
Interest income |
|
|
4,333 |
|
|
|
1,844 |
|
|
|
2,489 |
|
Interest expense |
|
|
(3,481 |
) |
|
|
(76 |
) |
|
|
(3,405 |
) |
Total other income |
|
|
10,767 |
|
|
|
1,855 |
|
|
|
8,912 |
|
Loss before income tax expense |
|
$ |
(29,748 |
) |
|
$ |
(13,132 |
) |
|
$ |
(16,616 |
) |
Revenue, Cost of Revenue and Gross Profit
Product revenue. Product revenue for the three months ended September 30, 2026 increased by $3.9 million to $5.1 million compared to $1.3 million for the three months ended September 30, 2025. We have recognized revenue of our radiopharmacies from the sale of nuclear medical doses for PET and SPECT scanning of $4.3 million and $1.3 million for the three months ended September 30, 2026 and 2025, respectively. The increase of $3.0 million was primarily attributable to (1) revenue of $0.8 million related to the acquisition of NuMed in January 2026, (2) revenue of $0.9 million related to the acquisition of ECNP in October 2025, and (3) an increase of $1.3 million related to the increase in sales of our nuclear medicine pipeline through PET Labs. With the acquisition of Renergen in January 2026, we recognized revenue from the sale of LNG of $0.9 million for the three months ended September 30, 2026.
Collaboration revenue. We did not recognize any collaboration revenue from the TerraPower R&D Agreement for the three months ended September 30, 2026 and 2025.
Cost of revenue. We have recognized the related cost of revenue of our radiopharmacies and Renergen for the same periods. The cost of revenue was $4.3 million and $1.0 million for the three months ended September 30, 2026 and 2025, respectively. The increase in cost of revenue of $3.3 million was primarily attributable to (1) the acquisitions of ECNP of $0.8 million, (2) the acquisitions of Numed of $0.5 million, (3) the acquisition of Renergen of $1.7 million and (4) an increase of $0.3 million related to the increase in sales of our nuclear medicine pipeline through PET Labs.
Gross profit. Gross profit for the three months ended September 30, 2026 increased by $0.6 million to $0.8 million compared to $0.2 million for the three months ended September 30, 2025. The gross profit from our radiopharmacies increased from $0.2 million to $1.6 million while gross margin increased from 19% to 38% over this period primarily attributable to the acquisitions of Numed and ECNP as well as higher sales volumes at PET Labs spreading fixed operating costs over a larger revenue base. These increases were partially offset by a Helium and LNG segment loss of $0.8 million related to the acquisition of Renergen in January 2026 which resulted in a negative gross margin of 96% for that segment. The negative gross margin was primarily attributable to fixed operating costs associated with operating and maintaining the production facility while production volumes remained below levels necessary to absorb such costs. Management expects margins in the Helium and LNG segment to improve in 2027 as production volumes increase and fixed operating costs are absorbed over a larger production base.
Research and Development Expenses
The following table summarizes our research and development expenses for the three months ended September 30, 2026 and 2025:
|
|
Three Months Ended September 30, |
|
|
|
|
||||||
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|||
Personnel-related costs |
|
$ |
2,138 |
|
|
$ |
1,114 |
|
|
$ |
1,024 |
|
Manufacturing engineering |
|
|
793 |
|
|
|
1,121 |
|
|
|
(328 |
) |
Contract services, consulting and professional |
|
|
2,372 |
|
|
|
42 |
|
|
|
2,330 |
|
Facility and depreciation expenses |
|
|
1,458 |
|
|
|
793 |
|
|
|
665 |
|
Exploratory costs |
|
|
408 |
|
|
|
— |
|
|
|
408 |
|
Other expenses |
|
|
67 |
|
|
|
28 |
|
|
|
39 |
|
Total research and development expenses |
|
$ |
7,236 |
|
|
$ |
3,098 |
|
|
$ |
4,138 |
|
45
Research and development expenses were $7.2 million for the three months ended September 30, 2026, compared to $3.1 million for the three months ended September 30, 2025. The overall increase of $4.1 million was primarily attributable to the following:
Selling, General and Administrative Expenses
Selling, general and administrative expenses were $34.1 million for the three months ended September 30, 2026, compared to $12.1 million for the three months ended September 30, 2025. The overall increase of $21.9 million was primarily attributable to the following:
Other Income (Expense)
Other income for the three months ended September 30, 2026 was $10.8 million, which includes interest income of $4.3 million, a gain on extinguishment of convertible notes payable of $11.3 million and $0.2 million from the change in fair value of the convertible notes payable, partially offset by a foreign exchange transaction loss of $0.5 million, an expense of $1.0 million due to change in fair value of our investments and interest expense of $3.5 million.
Other income for the three months ended September 30, 2025 was $1.9 million, which includes a $0.2 million gain from the change in fair value of the convertible notes payable and interest income of $1.8 million, partially offset by interest expense of $0.1 million.
Comparison of the Nine Months Ended September 30, 2026 and 2025
The following table summarizes our results of operations for the nine months ended September 30, 2026 and 2025:
|
|
Nine Months Ended September 30, |
|
|
|
|
||||||
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|||
Product revenue |
|
$ |
13,627 |
|
|
$ |
3,571 |
|
|
$ |
10,056 |
|
Collaboration revenue |
|
|
800 |
|
|
|
— |
|
|
|
800 |
|
Total revenue |
|
|
14,427 |
|
|
|
3,571 |
|
|
|
10,856 |
|
Cost of revenue |
|
|
10,487 |
|
|
|
2,430 |
|
|
|
8,057 |
|
Gross profit |
|
|
3,940 |
|
|
|
1,141 |
|
|
|
2,799 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|||
Research and development |
|
|
19,324 |
|
|
|
5,508 |
|
|
|
13,816 |
|
Selling, general and administrative |
|
|
84,214 |
|
|
|
30,541 |
|
|
|
53,673 |
|
Total operating expenses |
|
|
103,538 |
|
|
|
36,049 |
|
|
|
67,489 |
|
Other (expense) income: |
|
|
|
|
|
|
|
|
|
|||
Foreign exchange transaction loss |
|
|
(1,610 |
) |
|
|
(113 |
) |
|
|
(1,497 |
) |
Change in fair value of share liability |
|
|
— |
|
|
|
(200 |
) |
|
|
200 |
|
Change in fair value of convertible notes payable |
|
|
(3,863 |
) |
|
|
(64,542 |
) |
|
|
60,679 |
|
Change in fair value of investments |
|
|
138 |
|
|
|
— |
|
|
|
138 |
|
Gain on extinguishment of convertible notes |
|
|
11,250 |
|
|
|
— |
|
|
|
11,250 |
|
Interest income |
|
|
10,091 |
|
|
|
3,283 |
|
|
|
6,808 |
|
Interest expense |
|
|
(6,984 |
) |
|
|
(245 |
) |
|
|
(6,739 |
) |
Total other income (expense) |
|
|
9,022 |
|
|
|
(61,817 |
) |
|
|
70,839 |
|
Loss before income tax expense |
|
$ |
(90,576 |
) |
|
$ |
(96,725 |
) |
|
$ |
6,149 |
|
Revenue, Cost of Revenue and Gross Profit
Product revenue. Product revenue for the nine months ended September 30, 2026 increased by $10.1 million to $13.6 million compared to $3.6 million for the nine months ended September 30, 2025. We have recognized revenue of our radiopharmacies from the sale of nuclear medical doses for PET and SPECT scanning of $11.5 million and $3.6 million for the nine months ended September 30, 2026 and 2025, respectively. The increase of $7.9 million was primarily attributable to (1) revenue of $2.2 million related to the acquisition of NuMed in January 2026, (2) revenue of $2.9 million related to the acquisition of ECNP in October 2025, and (3)
46
an increase of $2.8 million related to the increase in sales of our nuclear medicine pipeline through PET Labs. With the acquisition of Renergen in January 2026, we recognized revenue from the sale of LNG of $2.1 million for the nine months ended September 30, 2026.
Collaboration revenue. We recognized $0.8 million in collaboration revenue from the TerraPower R&D Agreement for the nine months ended September 30, 2026. No collaboration revenue was recognized for the nine months ended September 30, 2025.
Cost of revenue. We have recognized the related cost of revenue of our radiopharmacies and Renergen for the same periods. The cost of revenue was $10.5 million and $2.4 million for the nine months ended September 30, 2026 and 2025, respectively. The increase in cost of revenue of $8.1 million was primarily attributable to (1) cost of revenue of $1.7 million related to the acquisitions of ECNP in October 2025, (2) cost of revenue of $1.6 million related to the acquisitions of Numed in January 2026, (3) cost of revenue of $4.0 million related to the acquisition of Renergen in January 2026 and (4) an increase of $0.8 million related to the increase in sales of our nuclear medicine pipeline through PET Labs.
Gross profit. Gross profit for the nine months ended September 30, 2026 increased by $2.8 million to $3.9 million compared to $1.1 million for the nine months ended September 30, 2025. The gross profit from our radiopharmacies increased from $1.1 million to $5.0 million while gross margin increased from 32% to 44% over this period primarily attributable to the acquisitions of Numed and ECNP as well as higher sales volumes at PET Labs spreading fixed operating costs over a larger revenue base. We also received $0.8 million from our collaboration with TerraPower. These increases were partially offset by a Helium and LNG segment loss of $1.9 million related to the acquisition of Renergen in January 2026 which resulted in a negative gross margin of 90% for that segment. The negative gross margin was primarily attributable to fixed operating costs associated with operating and maintaining the production facility while production volumes remained below levels necessary to absorb such costs. Management expects margins in the Helium and LNG segment to improve in 2027 as production volumes increase and fixed operating costs are absorbed over a larger production base.
Research and Development Expenses
The following table summarizes our research and development expenses for the nine months ended September 30, 2026 and 2025:
|
|
Nine Months Ended September 30, |
|
|
|
|
||||||
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|||
Personnel-related costs |
|
$ |
7,065 |
|
|
$ |
1,781 |
|
|
$ |
5,284 |
|
Manufacturing engineering |
|
|
1,440 |
|
|
|
1,246 |
|
|
|
194 |
|
Contract services, consulting and professional |
|
|
4,873 |
|
|
|
152 |
|
|
|
4,721 |
|
Facility and depreciation expenses |
|
|
4,226 |
|
|
|
2,030 |
|
|
|
2,196 |
|
Exploratory costs |
|
|
1,318 |
|
|
|
— |
|
|
|
1,318 |
|
Other expenses |
|
|
402 |
|
|
|
299 |
|
|
|
103 |
|
Total research and development expenses |
|
$ |
19,324 |
|
|
$ |
5,508 |
|
|
$ |
13,816 |
|
Research and development expenses were $19.3 million for the nine months ended September 30, 2026, compared to $5.5 million for the nine months ended September 30, 2025. The overall increase of $13.8 million was primarily attributable to the following:
Selling, General and Administrative Expenses
Selling, general and administrative expenses were $84.2 million for the nine months ended September 30, 2026, compared to $30.5 million for the nine months ended September 30, 2025. The overall increase of $53.7 million was primarily attributable to the following:
Other Income (Expense)
Other income for the nine months ended September 30, 2026 was $9.0 million, which includes a $11.3 million gain on extinguishment of convertible notes payable, interest income of $10.1 million and a gain from a change in the fair value of our investments of $0.1 million, partially offset by an expense of $3.9 million from the change in fair value of the convertible notes payable, interest expense of $7.0 million and a foreign exchange transaction loss of $1.6 million.
Other expense for the nine months ended September 30, 2025 was $61.8 million, which includes an expense of $64.5 million from the change in fair value of the convertible notes payable, an expense of $0.2 million from the change in fair value of share liability
47
related to the shares issuable to consultants, interest expense of $0.2 million and a foreign exchange transaction loss of $0.1 million, partially offset by interest income of $3.3 million.
Non-GAAP Financial Information
We use certain measures to assess the financial performance of our business, as well as to comply with the reporting requirements of the JSE. Certain of these measures are termed “non-GAAP measures” because they exclude amounts that are included in, or include amounts that are excluded from, the most directly comparable measure calculated and presented in accordance with GAAP, or are calculated using financial measures that are not calculated in accordance with GAAP. These non-GAAP measures include headline loss, and headline loss per common share.
An explanation of the relevance of the non-GAAP measure, a reconciliation of the non-GAAP measure to the most directly comparable measure calculated and presented in accordance with GAAP and a discussion of its limitations are set out below. We do not regard these non-GAAP measures as a substitute for, or superior to, the equivalent measure calculated and presented in accordance with GAAP or that calculated using financial measures that are calculated in accordance with GAAP and such measures may not be comparable to similarly titled measures used by other companies.
Headline Loss per Share
In connection with our secondary listing on the JSE, we are required to calculate and publicly disclose headline loss per share and diluted headline loss per share. Headline loss per share is calculated using net loss which has been determined in accordance with GAAP. Headline loss for the period represents the loss for the period attributable to our common stockholders adjusted for the remeasurements that are more closely aligned to the operating or trading results as set forth below, and headline loss per share represents headline loss divided by the weighted average number of shares of common stock outstanding.
The table below presents a reconciliation between net loss attributable to common stockholders to headline loss.
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Net loss attributable to ASP Isotopes Inc. shareholders |
|
$ |
(30,371 |
) |
|
$ |
(12,617 |
) |
|
$ |
(70,833 |
) |
|
$ |
(96,125 |
) |
Adjusted for: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Gain on extinguishment of convertible notes |
|
|
(11,250 |
) |
|
|
— |
|
|
|
(11,250 |
) |
|
|
— |
|
Change in fair value of share liability |
|
|
— |
|
|
|
71 |
|
|
|
— |
|
|
|
200 |
|
Change in fair value of convertible notes payable |
|
|
(164 |
) |
|
|
(173 |
) |
|
|
3,863 |
|
|
|
64,542 |
|
Change in fair value of equity investments |
|
|
988 |
|
|
|
— |
|
|
|
(138 |
) |
|
|
— |
|
Headline loss |
|
$ |
(40,797 |
) |
|
$ |
(12,719 |
) |
|
$ |
(78,358 |
) |
|
$ |
(31,383 |
) |
Weighted average common shares outstanding on which the net loss attributable to ASP Isotopes Inc. shareholders per share and headline loss per share has been calculated - basic and diluted |
|
|
143,385,783 |
|
|
|
88,552,309 |
|
|
|
128,891,373 |
|
|
|
75,985,507 |
|
Net loss per share, attributable to ASP Isotopes Inc. shareholders, basic and diluted |
|
$ |
(0.21 |
) |
|
$ |
(0.14 |
) |
|
$ |
(0.55 |
) |
|
$ |
(1.27 |
) |
Headline loss per share, attributable to ASP Isotopes Inc. shareholders, basic and diluted |
|
$ |
(0.28 |
) |
|
$ |
(0.14 |
) |
|
$ |
(0.61 |
) |
|
$ |
(0.41 |
) |
The above disclosure was prepared for the purpose of complying with the reporting requirements of the JSE and includes certain non-GAAP measures, such as headline loss and headline loss per common share, and related reconciliations.
Liquidity and Capital Resources
Sources of Liquidity
We have incurred net losses and negative cash flows from operations since our inception, and we expect to continue to incur significant and increasing net losses for the foreseeable future. We have principally financed our operations to date through the issuance of our common stock, including our IPO, and the issuance of convertible notes payable.
As of September 30, 2026, we had cash and cash equivalents of $201.7 million. We have not generated any revenue from the sale of our enriched isotopes, and our ability to generate product revenue from the sale of enriched isotopes sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future enriched isotopes.
We recognize product revenue from the sale of nuclear medical doses for PET and SPECT scanning in South Africa and the U.S. Our ability to generate product revenue from the sale of nuclear medical doses for PET and SPECT scanning sufficient to achieve profitability will depend on the successful expansion of production capabilities and commercialization of the results of that expansion. Effective with the acquisition of Renergen in January 2026, we also recognize revenue from the sale of helium and LNG. Our ability to generate revenue from the sale of helium and LNG sufficient to achieve profitability will depend on the successful expansion of production capabilities and commercialization of the results of that expansion. Renergen’s outstanding debt funding may also materially affect our liquidity. We also recognize collaboration revenue from our TerraPower R&D Agreement.
Future Funding Requirements
Based on our current operating plan, we estimate that our existing cash and cash equivalents, proceeds from short-term investments, as well as cash flow from operations, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months from the date the financial statements are issued and beyond. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of developing isotopes is costly, and the timing of progress and expenses in these development activities is uncertain.
48
Our future capital requirements will depend on many factors, including:
Developing and commercializing isotopes is a time-consuming, expensive and uncertain process that takes years to complete, and we may never achieve the necessary results required or obtain applicable regulatory approval for any isotopes or generate revenue from the sale of any future isotopes (assuming applicable regulatory approval is received). In addition, our future isotopes (assuming applicable regulatory approval is received) may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of isotopes that we do not expect to be commercially available until the fourth quarter of 2026. If we receive permits and licenses to enrich U-235 (which in itself is highly uncertain), we do not expect U-235 to be commercially available for at least several years, if ever. As a result, we may need substantial additional financing to support our continuing operations and further the development of and commercialization of our future isotopes.
Expansion of the production and distribution of nuclear medical doses for PET scanning is a time-consuming, expensive and uncertain process that may take years to complete. As a result, we may need substantial additional financing to support our continuing operations and further the development of and commercialization of future nuclear medical doses for PET scanning.
Large amounts of capital are required to support the growth in our business and operations in South Africa, including to maintain and progress toward full commercial operation of Phase 1 of the Virginia Gas Project, and for the construction and development of Phase 2 of our Virginia Gas Project, and long-term production and processing requires both significant capital expenditure and ongoing maintenance expenditure. Our revenues related to the sale of helium and LNG may vary significantly from period to period as a result of changes in volumes of production sold and commodity prices. Natural gas prices have historically been volatile. Lower commodity prices may not only decrease our revenues, but also potentially the amount of natural gas that we can produce economically. We plan to add reserves through drilling. Our ability to add reserves through drilling projects is dependent on many factors, including our ability to borrow or raise capital and procure materials, services and personnel. Phase 2 of the Virginia Gas Project requires a significant amount of capital and is currently estimated to cost in excess of $1.0 billion (including borrowing costs and general corporate costs during construction) based on our latest cost estimate, which could change based on inaccurate assumptions and changing economic and operating conditions. We intend to continue to pursue senior debt funding for Phase 2 of the Virginia Gas Project from institutional lenders, including the U.S. International Development Finance Corporation ("DFC") and Standard Bank of South Africa ("SBSA"). Renergen received a letter of conditional approval from the DFC, pursuant to the DFC’s application review process, for up to $500 million in senior secured debt financing (the “Commitment Letter”). On September 30, 2026, the DFC agreed to extend its commitment to permit the finalization of the finance agreement under the Commitment Letter to July 1, 2029. The financing under the Commitment Letter is expected to be conditional upon, among other things, certain equity investments; the right to use a portion of the real property on which the Phase 2 facilities and wells are located, whether through ownership, leases, easements, rights-of-way or similar arrangements; Tetra4's entry into business, construction and operational arrangements satisfactory to the lenders for the delivery of the Phase 2 facilities; established marketing plans for helium and LNG sales, including timing, volumes and pricing to comply with the financial covenants under the proposed debt facilities; entry into definitive helium and LNG offtake agreements providing contracted revenues sufficient to cover a percentage of the projected debt service under the proposed debt facilities; certain debt-to-equity ratios; and the receipt of certain regulatory approvals. The Commitment Letter is non-binding and subject to a number of terms and conditions, contingencies and uncertainties. There can be no assurance that we will ultimately enter into a binding definitive agreement with the DFC or that the terms of such agreement will not differ, possibly materially, from those described herein.
In addition, SBSA has previously indicated its willingness to consider supporting Phase 2 of the Virginia Gas Project for up to $250 million of senior debt funding. No binding definitive agreements have been executed with respect to either facility. There can be no assurance we will be able to obtain financing from the DFC or the SBSA for Phase 2 of the Virginia Gas Project on terms that are
49
favorable to us or at all. As a result, we may need substantial additional or alternative financing to support our continuing operations, ramp up production of Phase 1, and further the development of Phase 2 and commercialization of the Virginia Gas Project.
Until such time as we can generate significant revenue from sales of our future isotopes, nuclear medical doses for PET and SPECT scanning and sales of helium and LNG, if ever, we expect to finance our cash needs through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting severely diminished liquidity and credit availability, increased interest rates, inflationary pressures, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our future isotopes, future helium and LNG production and sales, future revenue streams or research programs or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our future isotopes and helium and LNG production even if we would otherwise prefer to develop and market such isotopes, helium and LNG ourselves.
Cash Flows
The following table summarizes our sources and uses of cash for each of the periods presented:
|
|
Nine Months Ended September 30, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Net cash provided by (used in): |
|
|
|
|
|
|
||
Operating activities(1) |
|
$ |
(66,449 |
) |
|
$ |
(19,935 |
) |
Investing activities |
|
|
(19,114 |
) |
|
|
(44,555 |
) |
Financing activities(2) |
|
|
34,065 |
|
|
|
107,485 |
|
Change in cash and cash equivalents |
|
$ |
(51,498 |
) |
|
$ |
42,995 |
|
(1) includes cash flows used in discontinued operations of $1.1 million and $0.8 million for the nine months ended September 30, 2026 and 2025, respectively.
(2) Includes cash flows provided by discontinued operations of $9.1 million for the nine months ended September 30, 2025.
(3) includes cash flows provided by discontinued operations of $45.9 million and $0.6 million for the nine months ended September 30, 2026 and 2025, respectively.
Operating Activities
Net cash used in operating activities was $66.4 million for the nine months ended September 30, 2026, including $1.1 million from discontinued operations, and was primarily attributable to our net loss from continuing operations of $91.6 million, adjusted for a gain on deconsolidation of $19.3 million, gain on extinguishment of convertible notes payable of $11.3 million, stock-based compensation expense of $18.6 million, amortization of right-of-use asset of $0.8 million, depreciation and amortization expense of $6.0 million, change in fair values of investments of $0.1 million, change in fair values for the convertible notes payable of $3.9 million, noncash interest on debt of $4.1 million, change in deferred taxes of $0.7 million and a $1.8 million change in our operating assets and liabilities.
Net cash used in operating activities was $19.9 million for the nine months ended September 30, 2025, and was primarily attributable to our net loss from continuing operations of $96.8 million, adjusted for stock-based compensation expense of $10.8 million, amortization of right-of-use asset of $0.4 million, depreciation expense of $0.9 million, issuance of common stock to a consultant with a fair value of $0.7 million, change in fair values for the convertible notes payable of $64.5 million and a $1.3 million change in our operating assets and liabilities.
Investing Activities
Net cash used in investing activities was $19.1 million for the nine months ended September 30, 2026 and was comprised of purchase of short-term investments of $35.4 million, purchase of Opeongo and ENDRA investment of $14.1 million, cash disposed of upon deconsolidation of Skyline of $44.7 million and the purchases of machinery and equipment, vehicles and construction in progress of $13.6 million, partially offset by maturity of short-term investments of $83.2 million and net cash provided by acquisitions of $4.9 million.
Net cash used in investing activities was $44.6 million for the nine months ended September 30, 2025, including $9.1 million from discontinued operations, and was comprised of the purchases of machinery and equipment, vehicles and construction in progress of $7.3 million, purchase of IsoBio investment of $5.0 million, investment in Skyline of $2.5 million, cash disposed of upon deconsolidation of Skyline of $8.9 million and the advancement of $30.0 million loan to Renergen prior to the close of the acquisition.
Financing Activities
Net cash provided by financing activities was $34.1 million for the nine months ended September 30, 2026, including $45.9 million from discontinued operations, and was comprised primarily of $0.2 million for the exercise of stock options, $0.1 million in proceeds from the issuance of notes payable, partially offset by principal payments on debt, finance leases and bank loans of $9.8 million, distribution to noncontrolling interest of Renergen of $1.5 million and distribution to noncontrolling interest in VIE of $0.5 million.
Net cash provided by financing activities was $107.5 million for the nine months ended September 30, 2025, including $0.6 million from discontinued operations. and was comprised primarily of $103.1 million in proceeds from the issuance of common stock net of issuance costs, $4.9 million in proceeds from the exercise of warrants and $1.0 million in principal payments on debt and finance leases.
50
Contractual Obligations and Commitments
Leases
We lease several facilities in the United States and South Africa for office, manufacturing and laboratory space under leases with current combined monthly rent payments of approximately $115,000 with terms expiring between October 31, 2026 and March 31, 2056. We also lease additional space on a short term basis in the United States, South Africa, United Kingdom, and Cayman Islands under leases with current combined monthly rent payments of approximately $32,000.
Promissory Note and Loans
In August 2025, we executed a promissory note payable with a finance company to fund a general liability insurance policy for $0.2 million. We assumed a promissory note in connection with the acquisition of Renergen in January 2026 to fund a general liability insurance policy for approximately $1.1 million. Periodically, we enter into loans to purchase motor vehicles and certain equipment. For the nine months ended September 30, 2026, we entered into new loans totaling $0.1 million. These loans are secured by the underlying assets included in property and equipment. Refer to Note 9 ("Debt") to our condensed consolidated financial statements in this Quarterly Report on Form 10-Q for information regarding interest rates and maturities.
QLE Convertible Notes
As previously discussed, QLE issued the 2025 Convertible Notes, which include certain contractual obligations and commitments. See Note 9 "Debt" for additional information.
Renergen Contractual Obligations and Commitments
As previously discussed, we acquired Renergen (and its indirect 94.5% equity ownership in Tetra4) in January 2026, which entities are subject to certain contractual obligations and commitments discussed further below. See also Note 9 "Debt" for additional information.
Certain Commitments to the South Africa Competition Commission
In connection with our acquisition of Renergen, we made certain commitments to the South Africa Competition Commission designed to address public interest concerns and promote historically disadvantaged persons (“HDP”) and worker ownership. These commitments to the South Africa Competition Commission include: (1) a moratorium on retrenchments of workers at Renergen’s operations for a period of two years from the merger closing date; and (2) a commitment to implement, within 12 months of the merger closing date, a trust for the benefit of qualifying workers employed by Renergen and certain HDP communities and people located within the production rights area of the Virginia Gas Project (the “HDP and Worker Trust”). Upon the effective implementation date of the HDP and Worker Trust, the HDP and Worker Trust are expected to hold an aggregate 5% of the issued shares in Tetra4 and Renergen is expected to hold 89.5% of the issued shares in Tetra4, subject to change in accordance with any capital raising activities of us, Renergen and/or Tetra4 following the merger closing date. In conjunction with the establishment of the HDP and Workers Trust, Tetra4 will issue an offsetting vendor financed loan to the HDP and Worker Trust. The HDP and Worker Trust will continue for the duration of the Production Right held by Tetra4, which will expire during 2042, unless extended.
Normal Course Operating Agreements
In addition, we entered into contracts in the normal course of business with vendors for services and products for operating purposes. These contracts do not contain any minimum purchase commitments and generally provide for termination after a notice period and, therefore, are not considered long-term contractual obligations. Payments due upon cancellation consist only of payments for services provided and expenses incurred up to the date of cancellation.
Off-balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.
Critical Accounting Policies and Significant Judgments and Estimates
Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. In preparing these financial statements, management is required to make estimates and assumptions that affect the reported amount of revenues, expenses, assets, liabilities and the disclosure of contingent liabilities. Actual results may differ from these estimates. Critical accounting estimates are those estimates that involve a significant level of estimation uncertainty and could have a material impact on our financial condition or results of operations.
The most significant estimates in our consolidated financial statements relate to stock-based compensation, fair value of convertible notes, equity and other investments, loss contingencies and the accounting for acquisitions, including goodwill. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may materially differ from these estimates and assumptions.
Stock-Based Compensation
Stock-based compensation represents a critical accounting estimate because determining the grant-date fair value of equity awards requires significant judgment and the use of assumptions that are inherently uncertain. For stock options and certain other equity awards, we estimate fair value using valuation models that require assumptions regarding expected stock price volatility, expected term, risk-free interest rates, forfeiture rates, and, where applicable, the fair value of our common stock. These assumptions are developed using a combination of historical information, market data, and management's expectations regarding future events.
Changes in these assumptions may materially affect the estimated fair value of awards granted and the amount of compensation expense recognized in future periods. For example, higher assumptions regarding expected volatility, longer expected terms, or increases in the estimated fair value of common stock would generally increase stock-based compensation expense. Such changes would primarily affect operating expenses, loss from operations, and net loss.
Fair Value Measurements of Convertible Notes
The valuation of convertible notes and related embedded features requires significant management judgment, particularly when observable market information is limited. The fair value estimates incorporate assumptions regarding expected volatility of our equity securities, market interest rates, credit risk, probability of conversion, expected term, and other market-based factors. Because certain
51
assumptions are not directly observable in the marketplace, changes in estimates could result in materially different fair value measurements.
Changes in these assumptions may result in increases or decreases to the carrying value of the convertible instruments and related liabilities, as well as non-cash gains or losses recognized in the statement of operations. As a result, changes in fair value assumptions could materially affect net loss and earnings per share in future reporting periods.
Equity and Other Investments
We hold investments in certain private and publicly traded companies. Determining the carrying value of these investments, particularly those that do not have readily determinable fair values, requires significant judgment. Our analysis considers available market transactions, financial performance of investee companies, financing activities, industry conditions, macroeconomic factors, and other indicators that may affect fair value or indicate impairment.
If actual operating performance of investee companies differs from our expectations, market conditions deteriorate, or other impairment indicators arise, we may be required to record impairment charges or valuation adjustments. Such adjustments could materially impact other income (expense), net income (loss), and the carrying amount of investments reported on our balance sheet.
Loss Contingencies
We are involved in various legal, regulatory, tax, and other matters arising in the normal course of business. The assessment of loss contingencies requires significant judgment regarding both the likelihood and magnitude of potential losses. When evaluating contingencies, management considers information obtained through investigations, communications with external legal counsel, settlement discussions, prior experience in similar matters, and the status of regulatory or judicial proceedings.
Because these matters are inherently uncertain, actual outcomes may differ significantly from current estimates. Future developments could require us to record additional accruals or reverse previously recorded amounts. Any such changes could materially affect operating expenses, accrued liabilities, net loss, and cash flows in the period in which new information becomes available.
Business Combinations, Intangible Assets and Goodwill
Accounting for acquisitions requires significant estimates and assumptions in determining the fair value of assets acquired and liabilities assumed. The most significant judgments typically relate to estimated future cash flows, customer retention rates, revenue growth assumptions, discount rates, royalty rates, useful lives of acquired intangible assets, and expected synergies. These estimates directly affect the amount assigned to identifiable intangible assets and goodwill.
Changes in assumptions used in purchase accounting could result in adjustments to the recorded values of acquired assets and liabilities during the measurement period. In addition, future changes in market conditions, operating results, or other factors may indicate that goodwill or intangible assets are impaired.
Goodwill impairment assessments are particularly sensitive to assumptions regarding revenue growth, operating margins, projected cash flows, and discount rates. A decline in expected future performance, increases in discount rates, adverse economic conditions, or changes in market multiples could result in impairment charges. Such charges could materially affect operating income, net income, total assets, and stockholders' equity.
See Note 2 to our condensed consolidated financial statements which discusses new accounting pronouncements.
52
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
We are a smaller reporting company as defined by Item 10 of Regulation S-K and are not required to provide the information otherwise required under this item.
Item 4. Controls and Procedures.
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, mean controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company on the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.
Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our Chief Executive Officer and Chief Financial Officer concluded that, as a result of material weaknesses identified in connection with our evaluation of our internal control over financial reporting, as previously disclosed in our Annual Report on Form 10-K (as amended) for the year ended December 31, 2025, our disclosure controls and procedures were not effective as of September 30, 2026.
Management’s Plan for Remediation of the Material Weakness
As previously described in Part II, Item 9A of our Annual Report, we began implementing a remediation plan to address the material weaknesses mentioned in such Annual Report. In order to remediate the material weaknesses, we expect to enhance our formal documentation over internal control procedures and management controls infrastructure to allow for more consistent execution of control procedures and hire additional accounting, and finance and information technology resources or consultants with public company experience. The material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.
Although we intend to complete the remediation process as promptly as possible, we cannot at this time estimate how long it will take to remediate the material weaknesses described in the Annual Report. We may discover additional material weaknesses that require additional time and resources to remediate, and we may decide to take additional measures to address the material weaknesses or modify the remediation steps described above.
Changes in Internal Control
Except for the activities taken related to the remediation of the material weaknesses described in the Annual Report, there has been no change in our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
53
PART II-OTHER INFORMATION
Item 1. Legal Proceedings.
Except as described in Note 11 ("Commitments and Contingencies") to our condensed consolidated financial statements in this Quarterly Report on Form 10-Q, we are not currently party to, and our property is not currently the subject of, any material pending legal matters or claims.
In addition, from time to time, we may become subject to arbitration, litigation or claims arising in the ordinary course of business. The results of any current or future claims or proceedings cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and litigation costs, diversion of management resources, reputational harm and other factors.
Item 1A. Risk Factors.
In addition to the information set forth in this Quarterly Report on Form 10-Q, including under the heading “Special Note Regarding Forward-Looking Statements,” the risks and uncertainties which could adversely affect our business, financial condition, results of operations and future growth prospects that we believe are most important for you to consider are discussed in “Part I, Item 1A—Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on April 10, 2026 and as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2026 and other reports that we file with the SEC, including our Quarterly Reports on Form 10-Q. The risks described in our Annual Report on Form 10-K for the year ended December 31, 2025 (as amended) and such other reports that we file with the SEC are not the only risks we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations.
In connection with the Merger, ENDRA filed a Registration Statement on Form S-4 (File No. 333-299256) (the "Registration Statement") with the SEC on October 2, 2026. The section entitled "Risk Factors" of the proxy statement/prospectus (which is preliminary and subject to completion) that is included in the Registration Statement contains additional risk factors relating to the Merger and Renergen’s business, among other matters, and is incorporated by reference herein, and should be read together with the risk factors set forth in this Quarterly Report on Form 10-Q. ENDRA intends to file amendments and/or supplements to the Registration Statement, which will contain important information about the Merger and Renergen. You should read the Registration Statement, including any amendments and supplements to it, and the definitive proxy statement/prospectus, when available, for additional information about the Merger, Renergen and the risks relating to them. The information set forth under the heading “Risk Factors—Risks Related to Renergen” in the Registration Statement is attached hereto for convenience as Exhibit 99.1 and incorporated herein by reference.
Except as set forth in the paragraph above, there have been no material changes to our risk factors as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025 (as amended).
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
Director and Officer Trading Arrangements
A portion of the compensation of the Company’s directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) is in the form of equity awards and, from time to time, directors and officers may engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.
Transactions in Company securities by directors and officers are required to be made in accordance with the Company’s insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in the Company’s securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
On
The Company has implemented mandatory, non-discretionary, "sell-to-cover" arrangements for the purpose of satisfying tax withholding obligations incurred upon the vesting of equity awards in certain of its equity award agreements. This arrangement provides for the automatic sale of shares of the Company’s common stock that would otherwise be issuable on each vesting date of a covered restricted stock award (RSA) in an amount necessary to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable withholding obligation. The number of shares that will be sold under these arrangements is not currently determinable as the number will vary based on the extent to which vesting conditions are satisfied, the market price of the Company’s common stock at the time of settlement and the potential future grant of additional RSAs subject to this arrangement.
Other than the trading arrangements described above, during the three months ended September 30, 2026, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) of ours adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
54
55
Item 6. Exhibits.
Exhibit Number |
|
Description |
2.1 |
|
Amendment No. 1 to Agreement and Plan of Merger, dated as of October 1, 2026, by and among ENDRA Life Sciences Inc., Kruger Merger Sub LLC, Renergen Limited, Noble Africa LLC and ASP Isotopes Inc. (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed by ENDRA Life Sciences Inc. on October 1, 2026). |
3.1
|
|
Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)). |
3.2 |
|
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K for the year ended December 31, 2023, filed on April 10, 2024). |
10.1 |
|
Second Amendment and Restatement Agreement, dated August 14, 2026, between Renergen Limited and The Standard Bank of South Africa Limited and countersigned by ASP Isotopes South Africa Proprietary Limited (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on August 20, 2026). |
10.2 |
|
Put Option Agreement, dated August 14, 2026, among The Standard Bank of South Africa Limited, ASP Isotopes Inc. and Renergen Limited (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on August 20, 2026). |
10.3* |
|
Fourth Addendum to the Term Loan Facility Agreement, between ASP Isotopes Inc., Renergen Limited and ASP Isotopes South Africa Proprietary Limited, dated May 28, 2026. |
10.4* |
|
Fifth Addendum to the Term Loan Facility Agreement, between ASP Isotopes Inc., Renergen Limited and ASP Isotopes South Africa Proprietary Limited, dated September 29, 2026. |
10.5 |
|
Non-Employee Director Compensation Policy effective July 1, 2026 (incorporated by reference to Exhibit 10.5 to the Company's Current Report on Form 10-Q filed on August 14, 2026). |
10.6 |
|
Form of Securities Exchange Agreement by and among ASP Isotopes Inc., Quantum Leap Energy LLC and the person or entity identified on the signature page thereto (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 16, 2026). |
10.7* |
|
Sale, Subscription And Shareholders’ Agreement between Mahlako Gas Energy Proprietary Limited and Renergen Limited and Tetra4 Proprietary Limited. |
31.1* |
|
Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended. |
31.2* |
|
Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended. |
32.1** |
|
Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
99.1* |
|
Risks Related to Renergen |
101.INS |
|
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
101.SCH |
|
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* Exhibits filed herewith.
** Exhibits furnished herewith.
+ Management contract or compensatory plan or arrangement.
# Certain schedules, annexes and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company will furnish copies of any such schedules, annexes and exhibits to the SEC upon request.
56
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
ASP Isotopes Inc. |
|
|
|
|
|
|
Date: November 16, 2026 |
By: |
/s/ Paul E. Mann |
|
|
|
Paul E. Mann |
|
|
|
Chief Executive Officer, Executive Chairman and Director |
|
|
|
(Principal Executive Officer) |
|
|
|
|
|
Date: November 16, 2026 |
By: |
/s/ Heather Kiessling |
|
|
|
Heather Kiessling |
|
|
|
Chief Financial Officer |
|
|
|
(Principal Financial and Accounting Officer) |
|
57